• If you are having problems logging in please use the Contact Us in the lower right hand corner of the forum page for assistance.

Two cases of BSE in the same herd in Czech Republic

Help Support Ranchers.net:

rkaiser

Well-known member
Joined
Feb 14, 2005
Messages
1,958
Reaction score
0
Location
Calgary Alberta
Finally hey R2. Undisputable proof that feed transmission is the cause of BSE. :lol: :lol: :lol:

Too bad we couldn't gather up some cash and send the only true BSE investigator in the world to Krasna Hora in the Central Bohemian district of Pribram. Maybe he would find some environmental problems there like he has in every other area he has visited with TSE problems.
 

flounder

Well-known member
Joined
Sep 3, 2005
Messages
2,631
Reaction score
0
Location
TEXAS
> This confirms experience from other countries that another sick animal is

> likely to appear in one herd where the same feed could have been used.



DON'T TELL OLD RON THAT :shock:



“Even at the height of BSE infection in Europe and the United Kingdom, it was extremely rare to have more than one animal in the same herd affected with BSE. Therefore USDA believes it is extremely unlikely that this imported cow would have been infected,” said DeHaven.


http://www.omakchronicle.com/agriculture/canadianbeef.htm




DeHaven and the CFIA said the risk of finding another BSE case from the infected cow's birth herd is very small. "Finding multiple cases of BSE in a single birth cohort is rare, based on international experiences," the CFIA said. DeHaven called it "extremely unlikely" that the imported animal would have had BSE.



http://www.cidrap.umn.edu/cidrap/content/other/bse/news/jan1005bse.html




A BSE case born in May 2002
BSE has been diagnosed in a Holstein Friesian cross cow, born on 1 May
2002. The case was identified under the current compulsory testing
programme for all animals born after 31 July 1996 slaughtered as cohorts of
confirmed BSE cases. This animal was included in the cohort of the BSE
case born on 3 October 2001 on the same farm and confirmed on 1 March
2005. This case born on 1 May 2002 was born on the same farm in Dyfed
and it remained on this farm until it was submitted for slaughter on 12 May
2005. Disease was officially confirmed on 27 May 2005. The animal was
aged 36 months at slaughter.
This is the most recently born case of BSE confirmed in the UK. The previous
most recent case was the related case born on 3 October 2001.
Another case born on the same farm on 28 September 2001 has been
confirmed on 27 May 2005 in the same cohort. This is the first time that the
UK has confirmed three cases born after July 1996 with the same farm of
origin. Defra will be following up detailed epidemiological analysis of this
case.
This case is being drawn to the attention of SEAC and Professor William Hill.
Professor Hill is currently carrying out an independent assessment of the
possible causes of BSE cases born after the reinforced feed ban of August
1996 (BARBs) at the request of Defra.

http://www.defra.gov.uk/animalh/bse/controls-eradication/barbinfo/01-05-2002.pdf





TSS
 

Kathy

Well-known member
Joined
Feb 11, 2005
Messages
837
Reaction score
0
Location
Home on the Range, Alberta
One need not sent Mark Purdey to the Pribram District of the Czech Republic to learn that this area has a history rich in URANIUM mining.

Here are some links and articles for you to read, if you care.

Link: http://www.muzeum-pribram.cz/jazyky/anglicky/anglicky.html
The exploitation of the historical silver district and the extraction of uranium deposit after 1948 are documented here.....
(Metal Mines of Příbram) and Uranové doly Příbram (Uranium Mines of Příbram) are also here. The visitors can see some exhibits from the fields of mining, measuring and rescue equipment and by samples of silver, lead and uranium ores. This exhibition of the museum also recalls the infamous part of the history of uranium mining, when political prisoners were forced inhumanely to work in the uranium mines after the revolution in February 1948.

Link:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?md=Retrieve&db=pubmed&dopt=Abstract&list_uids=1754830&query_hl=2
Risks of malignant neoplasms in workers in Czechoslovak uranium mines

Vich Z, Dienstbier Z.

ZUNZ Uranoveho prumyslu, oddeleni nemoci z povolani, Pribram.

The authors present a historical account on the findings which made it possible to define the most serious occupational disease in miners in uranium mines--bronchogenic carcinoma. In 1952-61 44 cases of lung cancer were reported in conjunction with radioactive substances, in 1962-85 already 1511 patients were recompensated. Z. Vich found in a prospective epidemiological survey that of 4803 workers who left for preventive reasons work places involving risk in 1968-75 20.5% died by 1985. The mortality rate from lung tumors was 3.5 times higher than in the male population of the Czech Republic. The authors analyze occupational risk indicators important for the prevention of this occupational disease. From the medical aspect the restriction of mining in uranium mines is welcome, as the work involves a high risk.

PMID: 1754830 [PubMed - indexed for MEDLINE]


Link: http://www.gli.cas.cz/igcp/CZ_IGCP1_files%5Cred_08.htm
(d) The interaction between uranium and bitumens and radiation-induced changes in bitumen structure and chemical composition has been studied in the Pribram uranium deposit. It has been shown that bitumens efficiently immobilize uranium and other natural radionuclides in hydrothermal solutions. The results indicate that bitumens may be effectively used as a sealing material of high-grade radioactive wastes stored in underground repository sides (Kribek et al., 2000).



The distribution of uranium over Europe: geological and environmental significance
Authors: Plant, J.A.; Reeder, S.; Salminen, R.; Smith, D.B.; Tarvainen, T.; De Vivo, B.; Petterson, M.G.

Source: Applied Earth Science, Volume 112, Number 3, December 2003, pp. 221-238(18)

Publisher: Maney Publishing

Abstract:

The variation of baseline levels of uranium in soil and stream sediments over Europe is described, based on new data prepared by the Forum of European Geological Surveys (FOREGS). The samples have been collected and analysed according to the protocols established for the International Union of Geological Sciences/International Association of Geochemistry and Cosmochemistry (IUGS/IAGC) Working Group on Global Geochemical Baselines. The baseline levels of U vary between 0·21 to 53 mg kg-1 in topsoils, 0·19 to 30 mg kg-1 in subsoils and < 1 to 59 mg kg-1 in stream sediments. There is generally good agreement between the levels of U in the three sample types, and the median concentration in all three media is approximately 2 mg kg-1. The most anomalous baseline levels occur over the Variscan orogen, especially areas into which late postorogenic radiothermal high heat production (HHP) granites were emplaced. Spiderdiagrams based on trace element levels and rare earth element (REE) plots, confirm the association between the highest U anomalies and evolved radiothermal granites. High values are also associated with parts of the Alpine terrain especially in Slovenia, where there are historical U workings, and Southern Italy, where high values of U reflect contemporary volcanism. In contrast, much of the Caledonides of North West Europe and the Precambrian of the Baltic Shield and East European craton and its overlying sedimentary cover have very low values, generally < 4 mg kg-1. The results suggest that the main concern for the environment and human health from U, and the Th and K with which it is generally associated, is the naturally occurring total gamma radiation and radon potential associated with radiothermal granites. This is likely to be especially important where the granites are mineralised and have been worked historically, for example in the North West of the Iberian Peninsula where U and its decay products are likely to be more dispersed in the surface environment. The study also indicates the value of multielement data in distinguishing between anthropogenic and naturally occurring anomalies.
Keywords: URANIUM; EUROPE; DISTRIBUTION


published by WISE News Communique on February 9, 1990

Czechoslovakian uranium miners protest

On 21 January, 500 uranium miners gathered at Pribram, one of the uranium mining centers in Czechoslovakia.
(326-327.3264) WISE Amsterdam - They were there to demand disclosure of the dangers posed by radiation to their health as well as to demand better social security. The miners do not have confidence in the mines administration staffs and the government's health department, which is still the same one that existed before the revolution. They have decided, instead, to help themselves.

The miners have handed over a list of demands to the health department and are willing to strike if a parliamentary commission is not set up to deal with their demands.

In total, 30,000 people are employed in Czechoslovakian uranium mining. About half of those work in underground mines and the uranium mills. In order to find out more about the health and social situation of these miners, a questionnaire has been set up by strike committees. The questionnaire will be given to all active and former miners.

It is known that although many workers came to the mines because of the high wages, prisoners have been forced to work there. Working in the mines (for ten years) is also a way for conscientious objectors to get around serving in the army.

After 3200 working shifts (or 15 to 17 years) in the underground mines, workers are employed on the surface - but this is also dangerous as high levels of radiation have been found in some of the offices and at the uranium mills. Workers become pensioners at the age of 55. There is no unemployment insurance, so if uranium mining should be reduced due to lower uranium needs of the Soviet Union in the next few years there will be no unemployment relief for the miners.

A former uranium miner who worked in the mines for thirty years, beginning in 1947, said, "We have been a group of 18 miners, 17 of them died from lung cancer, I am the only one who survived." Another miner was quoted as saying, "When they found a radiation-induced disease of my blood, they did not tell me the results of the investigation. They made false diagnoses to prevent recognition of an occupational disease."

Source and Contact: Peter Diehl, Schulstr. 13, 7881 Herrischried, West Germany.

Providing false diagnoses to prevent recognition of a disease. Yes, this sounds all to familiar.

Even Dr. Stanley Prusiner, (the father of the term Prion) has stated within his latest research, some surprising findings related to a uranium based compound:

“Evidence for assembly of prions with left-handed B-helices into trimers”, authors – Cedric Govaerts, Holger Wille, Stanley Prusiner, and Fred E. Cohen.

Although uranyl acetate is generally used as a negative stain for EM samples, it was surprising to observe that 2D crystals of prions specifically bind these ions near the center of the unit cell. This unexpected behavior provided evidence for a trimeric arrangement of PrP 27–30 monomers. We examined our model for possible uranyl-binding sites. Uranyl acetate is known to bind negatively charged side chains, but with only one Asp present in the -helical region of the PrP 27–30 model and none in the PrPSc106 model, uranyl acetate binding must occur through a different mechanism if it binds to the conformationally plastic region of PrP. Left-handed -helices expose backbone carbonyl moieties on each turn. In the center of the trimers, these moieties are often involved in the multimerization interface through H bonds with polar side chains of the neighboring monomer. Analysis of the -helical trimeric model shows that the distances between the carbonyls near the center and their interacting side chains provide suitable functionality to coordinate uranyl ions, either by replacing coordinated waters or by competing with the acetate counterion (38). In our model of PrP 27–30, Q90, H110, and D143 could be used to coordinate three to six uranyl acetate ions per trimer. This binding mode would place electron-dense uranyl ions in the center of the image, colocating with the densities observed in the EM maps.”
 

Kathy

Well-known member
Joined
Feb 11, 2005
Messages
837
Reaction score
0
Location
Home on the Range, Alberta
What does Saskatchewan, Canada have in common with the Pribram District?

Uranium deposits and mining, and surprisingly, it is also a hot spot for Chronic Wasting Disease.

The cow diagnosed in Northern AB with BSE, was born and raised in the Lloydminster, SK area. This area is rich in Oil and Gas activities and is situated near uranium mines/deposits.

I just heard someone on the radio this morning, (Dec. 1, 2005) speaking about the Turner Vally, AB Canada, (half acre of Hell - location of the first intense oil and gas activity in Alberta), and the contamination that is there (or should I say allegedly there??). A spokesperson (not sure yet who exactly she represented) this morning on QR77 stated that the radioactive levels found there could be due to the naturally occurring uranium and its' degradable isoforms. What? naturally occurring uranium deposits. Yes, she went on to state, "that most of all of Alberta is sitting on naturally occurring uranium".

AB has a program for the oil and gas industry workers, called NORM. NORM stands for "naturally occcurring radio-active material".

Beware ranchers who allow the spreading of drilling mud on you land, and flaring. You are getting some stuff you don't want, and they are not telling you. Saskatchewan has legislation which states you "should not permit the grazing of livestock on lands for a minimum of one year after the spreading of drilling mud from oil wells. I can't imagine anyone is actually enforcing this rule, and certainly, there are few if any that even know about it.

Mark Purdey has done some sampling of vegetation, soil, antlers, etc. in Saskatchewan in areas with and without CWD. You can check out his findings at: www.markpurdey.com under research articles. (Abstract below).

Elevated silver, barium and strontium in antlers, vegetation and soils sourced from CWD cluster areas; Do Ag/Ba/Sr piezoelectric crystals represent the transmissible pathogenic agent in TSEs?

Mark Purdey, High Barn Farm, Elworthy, Taunton, Somerset, TA43PX, UK.

Tel; 00 44 1984 656832. Email; [email protected]

High levels of Silver (Ag), Barium (Ba) and Strontium (Sr) and low levels of copper (Cu) have been measured in the antlers, soils and pastures of the deer that are thriving in the chronic wasting disease (CWD) cluster zones in North America in relation to the areas where CWD and other transmissible spongiform encephalopathies (TSEs) have not been reported. The elevations of Ag, Ba and Sr were thought to originate from both natural geochemical and artificial pollutant sources - stemming from the common practise of aerial spraying with 'cloud seeding' Ag or Ba crystal nuclei for rain making in these drought prone areas of North America, the atmospheric spraying with Ba based aerosols for enhancing / refracting radar and radio signal communications as well as the spreading of waste Ba drilling mud from the local oil/gas well industry across pastureland. These metals have subsequently bioconcentrated up the foodchain and into the mammals who are dependent upon the local Cu deficient ecosystems. A dual eco-prerequisite theory is proposed on the aetiology of TSEs which is based upon an Ag, Ba, Sr or Mn replacement binding at the vacant Cu/Zn domains on the cellular prion protein (PrP)/sulphated proteoglycan molecules which impairs the capacities of the brain to protect itself against incoming shock bursts of sound and light energy. Ag/Ba/Sr chelation of free sulphur within the biosystem inhibits the viable synthesis of the sulphur dependent proteoglycans, which results in the overall collapse of the Cu mediated conduction of electric signals along the PrP-proteoglycan signalling pathways; ultimately disrupting GABA type inhibitory currents at the synapses/end plates of the auditory / circadian regulated circuitry, as well as disrupting proteoglycan co-regulation of the growth factor signalling systems which maintain the structural integrity of the nervous system. The resulting Ag, Ba, Sr or Mn based compounds seed piezoelectric crystals which incorporate PrP and ferritin into their structure. These ferrimagnetically ordered crystals multi-replicate and choke up the PrP-proteoglycan conduits of electrical conduction throughout the CNS. The second stage of pathogenesis comes into play when the pressure energy from incoming shock bursts of low frequency acoustic waves from low fly jets, explosions, earthquakes, etc, (a key eco-characteristic of TSE cluster environments) are absorbed by the rogue 'piezoelectric' crystals, which duly convert the mechanical pressure energy into an electrical energy which accumulates in the crystal-PrP-ferritin aggregates (the fibrils) until a point of 'saturation polarization' is reached. Magnetic fields are generated on the crystal surface, which initiate chain reactions of deleterious free radical mediated spongiform neuro-degeneration in surrounding tissues. Since Ag, Ba, Sr or Mn based piezoelectric crystals are heat resistant and carry a magnetic field inducing pathogenic capacity, it is proposed that these ferroelectric crystal pollutants represent the transmissible, pathogenic agents that initiate TSE.

Mark Purdey - March 25th 2004
 

Kathy

Well-known member
Joined
Feb 11, 2005
Messages
837
Reaction score
0
Location
Home on the Range, Alberta
R2, don't you wonder if there is a connection between these prion diseases and imbalances/or contamination of metals. It seems that everywhere you look there is a source for these rogue metals (near TSE clusters).

Just like the Czech cases which you posted here, the area is well-known for mining uranium. What a coincidence!
 

Kathy

Well-known member
Joined
Feb 11, 2005
Messages
837
Reaction score
0
Location
Home on the Range, Alberta
Hay, here we have more evidence of metals, mainly Mn - manganese, causing misfolding of the prion protein.

FASEB J. 2005 May;19(7):783-5. Epub 2005 Mar 9

Effect of transition metals (Mn, Cu, Fe) and deoxycholic acid (DA) on the conversion of PrPC to PrPres.
Kim NH, Choi JK, Jeong BH, Kim JI, Kwon MS, Carp RI, Kim YS.

Ilsong Institute of Life Science, Anyang, Kyounggi-do, South Korea.

The PMCA (protein misfolding cyclic amplification) technique has been shown to drive the amplification of misfolded prion protein by PrP(Sc) seeds during several cycles of incubation-sonication. Here, we report that cyclic amplification of normal hamster brain homogenates treated with a number of transition metals (manganese [Mn], copper [Cu], and iron [Fe]) leads to conversion of PrP(C) into protease-resistant PrP(res). The efficiency of PrP(res) formation and the glycoforms induced by Mn were different from those obtained by Cu and Fe. Previous results have shown higher Mn and lower Cu levels in the affinity-purified PrP(Sc) from the brain of prion diseases compared with normal hamster brain homogenates.

We focused on Mn because we observed higher levels of Mn in whole brain, mitochondria, and scrapie-associated fibril-enriched fractions from the brains of animals with prion disease. In the presence of minute quantities of Mn-induced PrP(res) template with a large amount of PrP(C), PrP(res) amplification is observed. A metal chelater, EDTA reverses the effect of Mn on PrP(res) amplification, suggesting that Mn may play a role in the formation of PrP(res). It has been proposed that metal-catalyzed oxidation of PrP leads to the oxidation of amino acids and extensive aggregation of oxidized PrP. Carboxyl acids such as deoxycholic acid (DA) are oxidized molecules produced by 3' oxidation pathway. In in vitro studies, the potent effect of Mn on PrP(res) amplification is augmented by DA in a dose-dependent manner.

On the basis of the evidence of the elevated Mn levels in scrapie-associated fibril (SAF)-enriched preparations from the brains of animals with prion disease, Mn-loaded PrP and oxidized molecules such as carboxyl acids may contribute to the formation of the scrapie isoform of PrP in prion diseases.
 

rkaiser

Well-known member
Joined
Feb 14, 2005
Messages
1,958
Reaction score
0
Location
Calgary Alberta
Right on R2. Genetic makeup is very likey part of the picture. Only a very few cows become BSE problematic in an area, just as very few humans become TSE problematic.

I can handle that.
 

rkaiser

Well-known member
Joined
Feb 14, 2005
Messages
1,958
Reaction score
0
Location
Calgary Alberta
R2
And it appears that while you might be be asymptomatic, you can still pass the disease on through blood to others, even if your genotype may -- just may -- be holding back disease onset or lengthening the incubation
.

Since I don't beleive in this transmission stuff R2; have you now decided to make ME out to be asymptomatic and able to pass something on. I'll tell ya, the only thing I want to pass when you talk like this is ------!
 

rkaiser

Well-known member
Joined
Feb 14, 2005
Messages
1,958
Reaction score
0
Location
Calgary Alberta
Of course I realised that R2, just couldn't resist the chance to use my lip.

Keep up girl.
 

flounder

Well-known member
Joined
Sep 3, 2005
Messages
2,631
Reaction score
0
Location
TEXAS
http://neurology.thelancet.com Published online October 31, 2005


Coexistence of multiple PrPSc types in individuals with

Creutzfeldt-Jakob disease

Magdalini Polymenidou, Katharina Stoeck, Markus Glatzel, Martin Vey, Anne Bellon, and Adriano Aguzzi

Summary

Background The molecular typing of sporadic Creutzfeldt-Jakob disease (CJD) is based on the size and glycoform

ratio of protease-resistant prion protein (PrPSc), and on PRNP haplotype. On digestion with proteinase K, type 1 and

type 2 PrPSc display unglycosylated core fragments of 21 kDa and 19 kDa, resulting from cleavage around amino

acids 82 and 97, respectively.

Methods We generated anti-PrP monoclonal antibodies to epitopes immediately preceding the differential proteinase

K cleavage sites. These antibodies, which were designated POM2 and POM12, recognise type 1, but not type 2, PrPSc.

Findings We studied 114 brain samples from 70 patients with sporadic CJD and three patients with variant CJD.

Every patient classified as CJD type 2, and all variant CJD patients, showed POM2/POM12 reactivity in the

cerebellum and other PrPSc-rich brain areas, with a typical PrPSc type 1 migration pattern.

Interpretation The regular coexistence of multiple PrPSc types in patients with CJD casts doubts on the validity of

electrophoretic PrPSc mobilities as surrogates for prion strains, and questions the rational basis of current CJD

classifications.


snip...


The above results set the existing CJD classifications

into debate and introduce interesting questions about

human CJD types. For example, do human prion types

exist in a dynamic equilibrium in the brains of affected

individuals? Do they coexist in most or even all CJD

cases? Is the biochemically identified PrPSc type simply

the dominant type, and not the only PrPSc species?


http://neurology.thelancet.com Published online October 31, 2005




what i been saying for years, that the diagnostic criteria differentiating between the nvCJD (i.e. 'the chosen ones') and the sCJD (i.e. 'the forgotten ones') has been terribly flawed from the beginning. .... full text html at bottom of this email, if you want the full text pdf with all the bells and whistles, please email me and i will send pdf....tss


HUMAN TSE USA 2005


Animal Prion Diseases Relevant to Humans (unknown types?)
Thu Oct 27, 2005 12:05
71.248.128.109


About Human Prion Diseases /
Animal Prion Diseases Relevant to Humans

Bovine Spongiform Encephalopathy (BSE) is a prion disease of cattle. Since 1986, when BSE was recognized, over 180,000 cattle in the UK have developed the disease, and approximately one to three million are likely to have been infected with the BSE agent, most of which were slaughtered for human consumption before developing signs of the disease. The origin of the first case of BSE is unknown, but the epidemic was caused by the recycling of processed waste parts of cattle, some of which were infected with the BSE agent and given to other cattle in feed. Control measures have resulted in the consistent decline of the epidemic in the UK since 1992. Infected cattle and feed exported from the UK have resulted in smaller epidemics in other European countries, where control measures were applied later.

Compelling evidence indicates that BSE can be transmitted to humans through the consumption of prion contaminated meat. BSE-infected individuals eventually develop vCJD with an incubation time believed to be on average 10 years. As of November 2004, three cases of BSE have been reported in North America. One had been imported to Canada from the UK, one was grown in Canada, and one discovered in the USA but of Canadian origin. There has been only one case of vCJD reported in the USA, but the patient most likely acquired the disease in the United Kingdom. If current control measures intended to protect public and animal health are well enforced, the cattle epidemic should be largely under control and any remaining risk to humans through beef consumption should be very small. (For more details see Smith et al. British Medical Bulletin, 66: 185. 2003.)

Chronic Wasting Disease (CWD) is a prion disease of elk and deer, both free range and in captivity. CWD is endemic in areas of Colorado, Wyoming, and Nebraska, but new foci of this disease have been detected in Nebraska, South Dakota, New Mexico, Wisconsin, Mississippi Kansas, Oklahoma, Minnesota, Montana, and Canada. Since there are an estimated 22 million elk and deer in the USA and a large number of hunters who consume elk and deer meat, there is the possibility that CWD can be transmitted from elk and deer to humans. As of November 2004, the NPDPSC has examined 26 hunters with a suspected prion disease. However, all of them appeared to have either typical sporadic or familial forms of the disease. The NPDPSC coordinates with the Centers for Disease Control and state health departments to monitor cases from CWD-endemic areas. Furthermore, it is doing experimental research on CWD transmissibility using animal models. (For details see Sigurdson et al. British Medical Bulletin. 66: 199. 2003 and Belay et al. Emerging Infectious Diseases. 10(6): 977. 2004.)


http://www.cjdsurveillance.com/abouthpd-animal.html


SEE STEADY INCREASE IN SPORADIC CJD IN THE USA FROM 1997 TO 2004. SPORADIC CJD CASES TRIPLED, and that is with a human TSE surveillance system that is terrible flawed. in 1997 cases of the _reported_ cases of cjd were at 54, to 163 _reported_ cases in 2004. see stats here;

p.s. please note the 47 PENDING CASES to Sept. 2005

p.s. please note the 2005 Prion D. total 120(8) 8=includes 51 type pending, 1 TYPE UNKNOWN ???

p.s. please note sporadic CJD 2002(1) 1=3 TYPE UNKNOWN???

p.s. please note 2004 prion disease (6) 6=7 TYPE UNKNOWN???


http://www.cjdsurveillance.com/resources-casereport.html


CWD TO HUMANS = sCJD ???


AS implied in the Inset 25 we must not _ASSUME_ that
transmission of BSE to other species will invariably
present pathology typical of a scrapie-like disease.

snip...

http://www.bseinquiry.gov.uk/files/yb/1991/01/04004001.pdf


ATYPICAL TSEs in USA CATTLE AND SHEEP ?


http://www.bseinquiry.gov.uk/files/sc/seac17/tab03.pdf


Infected and Source Flocks

As of August 31, 2005, there were 115 scrapie infected and source flocks (figure 3). There were 3 new infected and source flocks reported in August (Figure 4) with a total of 148 flocks reported for FY 2005 (Figure 5). The total infected and source flocks that have been released in FY 2005 are 102 (Figure 6), with 5 flocks released in August. The ratio of infected and source flocks released to newly infected and source flocks for FY 2005 = 0.69 :
1. In addition, as of August 31, 2005, 574 scrapie cases have been confirmed and reported by the National Veterinary Services Laboratories (NVSL), of which 122 were RSSS cases (Figure 7). This includes 55 newly confirmed cases in August 2005 (Figure 8). Fifteen cases of scrapie in goats have been reported since 1990 (Figure 9). The last goat case was reported in May 2005.

snip...

full text ;

http://www.aphis.usda.gov/vs/nahps/scrapie/monthly_report/monthly-report.html


SCRAPIE USA JULY 2005 UPDATE

AS of July 31, 2005, there were 120 scrapie infected soure flocks (figure 3). There were 16 new infected and source flocks reorted in July (Figure 4) with a total of 143 flocks reported for FY 2005 (Figure 5). The total infected and source flocks that have been released in FY 2005 are 89 (Figure 6), with 8 flocks released in July. The ratio of infected and source flocks released to newly infected and source flocks for FY = 0.62 : 1. IN addition, as of July 31, 2005, 524 scrapie cases have been confirmed and reported by the National Veterinary Services Laboratories (NVSL), of which 116 were RSSS cases (Figure 7). This includes 76 newly confirmed cases in July 2005 (Figure 8). Fifteen cases of scrapie in goats have been reported since 1990 (Figure 9). The last goat case was reported in May 2005. ...........

snip...

http://www.aphis.usda.gov/vs/nahps/scrapie/monthly_report/monthly-report.html


SCRAPIE USA JUNE 2005 UPDATE


AS of June 30, 2005, there were 114 scrapie infected and source flocks
(Figure 3). There were 14 new infected and source flocks reported in June
(Figure 4) with a total of 123 flocks reported for FY 2005 (Figure 5).


snip...


In addition, as of June 30, 2005, 448 scrapie cases have been confirmed and
reported by the National Veterinary Services Laboratories (NVSL), of which
106 were RSSS cases (Figure 7). This includes 81 newly confirmed cases in
June 2005 (Figure 8). Fifteen cases of scrapie in goats have been reported
since 1990 (Figure 9). The last goat case was reported in May 2005.


snip...end


http://www.aphis.usda.gov/vs/nahps/scrapie/monthly_report/monthly-report.html


From: TSS ()
Subject: SCRAPIE USA UPDATE MARCH - JUNE 2005
Date: August 24, 2005 at 7:03 pm PST

SCRAPIE USA MONTHLY REPORT 2005

AS of March 31, 2005, there were 70 scrapie infected source flocks (Figure
3). There were 11 new infected and source flocks reported in March (Figure
4) with a total of 51 flocks reported for FY 2005 (Figure 5). The total
infected and source flocks that have been released in FY 2005 are 39 (Figure
6), with 1 flock released in March. The ratio of infected and source flocks
released to newly infected and source flocks for FY 2005 = 0.76 : 1. IN
addition, as of March 31, 2005, 225 scrapie cases have been confirmed and
reported by the National Veterinary Services Laboratories (NVSL), of which
53 were RSSS cases (Figure 7). This includes 57 newly confirmed cases in
March 2005 (Figure 8). Fourteen cases of scrapie in goats have been reported
since 1990 (Figure 9). The last goat cases was reported in January 2005. New
infected flocks, source flocks, and flocks released or put on clean-up plans
for FY 2005 are depicted in Figure 10. ...

FULL TEXT ;

http://www.aphis.usda.gov/vs/nahps/scrapie/monthly_report/monthly-report.html


Published online before print October 20, 2005

Proc. Natl. Acad. Sci. USA, 10.1073/pnas.0502296102
Medical Sciences

A newly identified type of scrapie agent can naturally infect sheep with resistant PrP genotypes

( sheep prion | transgenic mice )

Annick Le Dur *, Vincent Béringue *, Olivier Andréoletti , Fabienne Reine *, Thanh Lan Laï *, Thierry Baron , Bjørn Bratberg ¶, Jean-Luc Vilotte ||, Pierre Sarradin **, Sylvie L. Benestad ¶, and Hubert Laude *
*Virologie Immunologie Moléculaires and ||Génétique Biochimique et Cytogénétique, Institut National de la Recherche Agronomique, 78350 Jouy-en-Josas, France; Unité Mixte de Recherche, Institut National de la Recherche Agronomique-Ecole Nationale Vétérinaire de Toulouse, Interactions Hôte Agent Pathogène, 31066 Toulouse, France; Agence Française de Sécurité Sanitaire des Aliments, Unité Agents Transmissibles Non Conventionnels, 69364 Lyon, France; **Pathologie Infectieuse et Immunologie, Institut National de la Recherche Agronomique, 37380 Nouzilly, France; and ¶Department of Pathology, National Veterinary Institute, 0033 Oslo, Norway


Edited by Stanley B. Prusiner, University of California, San Francisco, CA, and approved September 12, 2005 (received for review March 21, 2005)

Scrapie in small ruminants belongs to transmissible spongiform encephalopathies (TSEs), or prion diseases, a family of fatal neurodegenerative disorders that affect humans and animals and can transmit within and between species by ingestion or inoculation. Conversion of the host-encoded prion protein (PrP), normal cellular PrP (PrPc), into a misfolded form, abnormal PrP (PrPSc), plays a key role in TSE transmission and pathogenesis. The intensified surveillance of scrapie in the European Union, together with the improvement of PrPSc detection techniques, has led to the discovery of a growing number of so-called atypical scrapie cases. These include clinical Nor98 cases first identified in Norwegian sheep on the basis of unusual pathological and PrPSc molecular features and "cases" that produced discordant responses in the rapid tests currently applied to the large-scale random screening of slaughtered or fallen animals. Worryingly, a substantial proportion of such cases involved sheep with PrP genotypes known until now to confer natural resistance to conventional scrapie. Here we report that both Nor98 and discordant cases, including three sheep homozygous for the resistant PrPARR allele (A136R154R171), efficiently transmitted the disease to transgenic mice expressing ovine PrP, and that they shared unique biological and biochemical features upon propagation in mice. These observations support the view that a truly infectious TSE agent, unrecognized until recently, infects sheep and goat flocks and may have important implications in terms of scrapie control and public health.


--------------------------------------------------------------------------------

Author contributions: H.L. designed research; A.L.D., V.B., O.A., F.R., T.L.L., J.-L.V., and H.L. performed research; T.B., B.B., P.S., and S.L.B. contributed new reagents/analytic tools; V.B., O.A., and H.L. analyzed data; and H.L. wrote the paper.

A.L.D. and V.B. contributed equally to this work.

To whom correspondence should be addressed.

Hubert Laude, E-mail: [email protected]

www.pnas.org/cgi/doi/10.1073/pnas.0502296102


http://www.pnas.org/cgi/content/abstract/0502296102v1


From: TSS ()
Subject: Interspecies Transmission of Chronic Wasting Disease Prions to Squirrel Monkeys (Saimiri sciureus)
Date: October 19, 2005 at 8:33 am PST

0022-538X/05/$08.00+0 doi:10.1128/JVI.79.21.13794-13796.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Interspecies Transmission of Chronic Wasting Disease Prions to Squirrel Monkeys (Saimiri sciureus)
Richard F. Marsh,1, Anthony E. Kincaid,2 Richard A. Bessen,3 and Jason C. Bartz4*
Department of Animal Health and Biomedical Sciences, University of Wisconsin, Madison 53706,1 Department of Physical Therapy,2 Department of Medical Microbiology and Immunology, Creighton University, Omaha, Nebraska 68178,4 Department of Veterinary Molecular Biology, Montana State University, Bozeman, Montana 597183

Received 3 May 2005/ Accepted 10 August 2005

Chronic wasting disease (CWD) is an emerging prion disease of deer and elk. The risk of CWD transmission to humans following exposure to CWD-infected tissues is unknown. To assess the susceptibility of nonhuman primates to CWD, two squirrel monkeys were inoculated with brain tissue from a CWD-infected mule deer. The CWD-inoculated squirrel monkeys developed a progressive neurodegenerative disease and were euthanized at 31 and 34 months postinfection. Brain tissue from the CWD-infected squirrel monkeys contained the abnormal isoform of the prion protein, PrP-res, and displayed spongiform degeneration. This is the first reported transmission of CWD to primates.


--------------------------------------------------------------------------------

* Corresponding author. Mailing address: Department of Medical Microbiology and Immunology, Creighton University, 2500 California Plaza, Omaha, NE 68178. Phone: (402) 280-1811. Fax: (402) 280-1875. E-mail: [email protected] .

Deceased.


--------------------------------------------------------------------------------

Journal of Virology, November 2005, p. 13794-13796, Vol. 79, No. 21
0022-538X/05/$08.00+0 doi:10.1128/JVI.79.21.13794-13796.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.


http://jvi.asm.org/cgi/content/abstract/79/21/13794?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=cwd&searchid=1129736446553_4280&stored_search=&FIRSTINDEX=0&volume=79&issue=21&journalcode=jvi


Research Project: Transmission, Differentiation, and Pathobiology of Transmissible Spongiform Encephalopathies
Location: Virus and Prion Diseases of Livestock

Title: Experimental Second Passage of Chronic Wasting Disease (Cwd-Mule Deer) Agent to Cattle


Authors

Hamir, Amirali
Kunkle, Robert - bob
Miller, Janice - ARS RETIRED
Greenlee, Justin
Richt, Juergen


Submitted to: Journal Of Comparative Pathology
Publication Acceptance Date: July 25, 2005
Publication Date: N/A


Interpretive Summary: To compare the findings of experimental first and second passage of chronic wasting disease (CWD) in cattle, 6 calves were inoculated into the brain with CWD-mule deer agent previously (first) passaged in cattle. Two other uninoculated calves served as controls. Beginning 10-12 months post inoculation (PI), all inoculates lost appetite and weight. Five animals subsequently developed clinical signs of central nervous system (CNS) abnormality. By 16.5 months PI, all cattle had been euthanized because of poor prognosis. None of the animals showed microscopic lesions of spongiform encephalopathy (SE) but the CWD agent was detected in their CNS tissues by 2 laboratory techniques (IHC and WB). These findings demonstrate that inoculated cattle amplify CWD agent but also develop clinical CNS signs without manifestation of microscopic lesions of SE. This situation has also been shown to occur following inoculation of cattle with another TSE agent, namely, sheep scrapie. The current study confirms previous work that indicates that the diagnostic tests currently used for confirmation of bovine spongiform encephalopathy (BSE) in the U.S. would detect CWD in cattle, should it occur naturally. Furthermore, it raises the possibility of distinguishing CWD from BSE in cattle due to the absence of microscopic lesions and a unique multifocal distribution of PrPres, as demonstrated by IHC, which in this study, appears to be more sensitive than the WB.
Technical Abstract: To compare clinicopathological findings of first and second passage of chronic wasting disease (CWD) in cattle, a group of calves (n=6) were intracerebrally inoculated with CWD-mule deer agent previously (first) passaged in cattle. Two other uninoculated calves served as controls. Beginning 10-12 months post inoculation (PI), all inoculates lost appetite and lost weight. Five animals subsequently developed clinical signs of central nervous system (CNS) abnormality. By 16.5 months PI, all cattle had been euthanized because of poor prognosis. None of the animals showed microscopic lesions of spongiform encephalopathy (SE) but PrPres was detected in their CNS tissues by immunohistochemistry (IHC) and Western blot (WB) techniques. These findings demonstrate that intracerebrally inoculated cattle not only amplify CWD PrPres but also develop clinical CNS signs without manifestation of morphologic lesions of SE. This situation has also been shown to occur following inoculation of cattle with another TSE agent, scrapie. The current study confirms previous work that indicates the diagnostic techniques currently used for confirmation of bovine spongiform encephalopathy (BSE) in the U.S. would detect CWD in cattle, should it occur naturally. Furthermore, it raises the possibility of distinguishing CWD from BSE in cattle due to the absence of neuropathologic lesions and a unique multifocal distribution of PrPres, as demonstrated by IHC, which in this study, appears to be more sensitive than the WB.



http://www.ars.usda.gov/research/publications/publications.htm?seq_no_115=178318


[Docket No. 03-025IFA] FSIS Prohibition of the Use of Specified Risk Materials for Human Food and Requirement for the Disposition of Non-Ambulatory Disabled Cattle

03-025IFA
03-025IFA-2
Terry S. Singeltary


Page 1 of 17

From: Terry S. Singeltary Sr. [[email protected]]

Sent: Thursday, September 08, 2005 6:17 PM

To: [email protected]

Subject: [Docket No. 03-025IFA] FSIS Prohibition of the Use of Specified Risk Materials for Human Food and Requirements

for the Disposition of Non-Ambulatory Disabled Cattle

Greetings FSIS,

I would kindly like to submit the following to [Docket No. 03-025IFA] FSIS Prohibition of the Use of Specified Risk Materials for Human Food and

Requirements for the Disposition of Non-Ambulatory Disabled Cattle

THE BSE/TSE SUB CLINICAL Non-Ambulatory Disabled Cattle

Broken bones and such may be the first signs of a sub clinical BSE/TSE Non-Ambulatory Disabled Cattle ;

SUB CLINICAL PRION INFECTION

MRC-43-00

Issued: Monday, 28 August 2000

NEW EVIDENCE OF SUB-CLINICAL PRION INFECTION: IMPORTANT RESEARCH

FINDINGS RELEVANT TO CJD AND BSE

A team of researchers led by Professor John Collinge at the Medical

Research Council Prion Unit1 report today in the Proceedings of the

National Academy of Sciences, on new evidence for the existence of a

?sub-clinical? form of BSE in mice which was unknown until now.

The scientists took a closer look at what is known as the ?species

barrier? - the main protective factor which limits the ability of

prions2 to jump from one species to infect another. They found the mice

had a ?sub-clinical? form of disease where they carried high levels of

infectivity but did not develop the clinical disease during their normal

lifespan. The idea that individuals can carry a disease and show no

clinical symptoms is not new. It is commonly seen in conventional

infectious diseases.

Researchers tried to infect laboratory mice with hamster prions3 called

Sc237 and found that the mice showed no apparent signs of disease.

However, on closer inspection they found that the mice had high levels

of mouse prions in their brains. This was surprising because it has

always been assumed that hamster prions could not cause the disease in

mice, even when injected directly into the brain.

In addition the researchers showed that this new sub-clinical infection

could be easily passed on when injected into healthy mice and hamsters.

The height of the species barrier varies widely between different

combinations of animals and also varies with the type or strain of

prions. While some barriers are quite small (for instance BSE easily

infects mice), other combinations of strain and species show a seemingly

impenetrable barrier. Traditionally, the particular barrier studied here

was assumed to be robust.

Professor John Collinge said: "These results have a number of important

implications. They suggest that we should re-think how we measure

species barriers in the laboratory, and that we should not assume that

just because one species appears resistant to a strain of prions they

have been exposed to, that they do not silently carry the infection.

9/13/2005

2

Page 2 of 17

This research raises the possibility, which has been mentioned before,

that apparently healthy cattle could harbour, but never show signs of, BSE.

"This is a timely and unexpected result, increasing what we know about

prion disease. These new findings have important implications for those

researching prion disease, those responsible for preventing infected

material getting into the food chain and for those considering how best

to safeguard health and reduce the risk that theoretically, prion

disease could be contracted through medical and surgical procedures."

ISSUED FRIDAY 25 AUGUST UNDER EMBARGO. PLEASE NOTE THAT THE EMBARGO IS

SET BY THE JOURNAL.

FOR FURTHER INFORMATION CONTACT THE MRC PRESS OFFICE ON 020 7637 6011

(OFFICE HOURS) OR 07818 428297 OR 0385 774357 (OUT-OF-OFFICE-HOURS) OR

PROFESSOR JOHN COLLINGE ON 020 7594 3760. PLEASE NOTE THAT OWING TO

TRAVEL COMMITMENTS PROFESSOR COLLINGE WILL ONLY BE AVAILABLE UNTIL 16.30

ON FRIDAY 25 AUGUST AND CONTACTABLE AGAIN ON MONDAY 28 AUGUST VIA THE

MRC PRESS OFFICE. DR ANDREW HILL (A CO-AUTHOR ON THE PAPER) FROM THE

DEPARTMENT OF PATHOLOGY AT THE UNIVERSITY OF MELBOURNE WILL BE AVAILABLE

ON 00 61 3 8344 3995 (DURING OFFICE HOURS) OR 00 61 3 9443 0009

(OUT-OF-OFFICE HOURS). PLEASE NOTE THAT AUSTRALIA IS TEN HOURS AHEAD OF

UK TIME.

NOTES FOR EDITORS

Professor Collinge is a consultant neurologist and Director of the newly

formed MRC Prion Unit based at The Imperial College School of Medicine

at St Mary?s Hospital. He is also a member of the UK Government?s

Spongiform Encephalopathy Advisory Committee (SEAC). The MRC prion unit

is was set up in 1999, and its work includes molecular genetic studies

of human prion disease and transgenic modelling of human prion diseases.

Prions are unique infectious agents that cause fatal brain diseases such

as Creutzfeldt-Jakob disease (CJD) in humans and scrapie and BSE (mad

cow disease) in animals. In some circumstances prions from one species

of animals can infect another and it is clear that BSE has done this to

cause the disease variant CJD in the UK and France. It remains unclear

how large an epidemic of variant CJD will occur over the years ahead.

The strain of prion used here to infect the mice is the Sc237 strain

(also known as 263K) which infects hamsters, and until now was assumed

not to infect mice.

This research was funded by the Medical Research Council and Wellcome

Trust.

The Medical Research Council (MRC) is a national organisation funded by

the UK tax-payer. Its business is medical research aimed at improving

human health; everyone stands to benefit from the outputs. The research

it supports and the scientists it trains meet the needs of the health

services, the pharmaceutical and other health-related industries and the

academic world. MRC has funded work which has led to some of the most

significant discoveries and achievements in medicine in the UK. About

half of the MRC?s expenditure of £345 million is invested in over 50 of

its Institutes and Units, where it employs its own research staff. The

remaining half goes in the form of grant support and training awards to

individuals and teams in universities and medical schools.

The Wellcome Trust is the world's largest medical research charity with

a spend of some £600 million in the current financial year 1999/2000.

The Wellcome Trust supports more than 5,000 researchers, at 400

locations, in 42 different countries to promote and foster research with

the aim of improving human and animal health. As well as funding major

initiatives in the public understanding of science, the Wellcome Trust

is the country's leading supporter of research into the history of

medicine.

http://www.mrc.ac.uk/index/public_interest/public-press_office/public-press_releases_2000/public-mrc-43-00.htm

SNIP...FULL TEXT;

9/13/2005

Page 3 of 17

https://web01.aphis.usda.gov/regpublic.nsf/0/eff9eff1f7c5cf2b87256ecf000df08d?OpenDocument

PNAS | August 29, 2000 | vol. 97 | no. 18 | 10248-10253

Neurobiology

Species-barrier-independent prion replication in apparently

resistant species

Andrew F. Hill*, Susan Joiner*, Jackie Linehan*, Melanie Desbruslais*, Peter L. Lantos , and John Collinge*,

* Medical Research Council Prion Unit and Department of Neurogenetics, Imperial College School of Medicine at St. Mary's, London W2 1PG, United Kingdom; and

Department of Neuropathology, Institute of Psychiatry, London SE5 8AF, United Kingdom

Communicated by Charles Weissmann, Imperial College of Science, Technology, and Medicine, London, United Kingdom, June 23, 2000 (received for review January

20, 2000)

Abstract

Transmission of prions between mammalian species is thought to be limited by a "species barrier," which depends on differences in the primary structure of prion proteins in

the infecting inoculum and the host. Here we demonstrate that a strain of hamster prions thought to be nonpathogenic for conventional mice leads to prion replication to high

levels in such mice but without causing clinical disease. Prions pathogenic in both mice and hamsters are produced. These results demonstrate the existence of subclinical

forms of prion infection with important public health implications, both with respect to iatrogenic transmission from apparently healthy humans and dietary exposure to cattle

and other species exposed to bovine spongiform encephalopathy prions. Current definitions of the species barrier, which have been based on clinical end-points, need to be

fundamentally reassessed.

snip...

Discussion

Implication of Demonstration of Subclinical Prion Infection. In prion diseases, infectious titers in the brain rise progressively

throughout prolonged, clinically silent periods that precede the onset of disease. Thus asymptomatic animals may harbor

significant infectious titers in brain and other tissues. However, there may be subclinical, as distinct from such preclinical, forms of

prion infection, where animals become asymptomatic carriers of infectivity and do not develop clinical disease in their lifetimes (7,

28). Such carrier states are well recognized in other infectious diseases. However, in prion diseases, where incubation periods are

extremely prolonged, distinction between subclinical and preclinical states is more difficult. It certainly can be argued that animals

dying after a typical lifespan without clinical signs of prion disease but harboring high levels of infectivity represent the late

preclinical stage of "transmissions" where the "incubation period" exceeds the normal lifespan (29). The distinction between the

terms subclinical and preclinical is essentially a semantic one in this context. Here we use the term subclinical infection

operationally to refer to animals in which prion replication is occurring but which have not developed clinical signs of prion disease

during a normal lifespan.

We have demonstrated that conventional mice inoculated with Sc237 prions harbor high levels of PrPSc and high prion titers in

their brains without developing clinical signs of prion disease within their normal lifespan. These results imply the existence of

subclinical prion infections that can be induced by challenge with prions from another species. However, whether or not this

infectivity is classified as preclinical or subclinical, it has important public health implications. Iatrogenic transmission could occur

from apparently healthy humans who may harbor high prion titers and many animal species (including sheep, pigs, and poultry)

were exposed to BSE prions via contaminated feed and could have developed subclinical prion infection. It is known that BSE

9/13/2005

Page 4 of 17

prions retain their distinctive strain characteristics after passage in a number of other species including humans (4, 13), arguing

that such BSE passaged in species other than cattle also may be pathogenic to humans. The possibility that subclinical BSE might

be present in other species and thereby present a threat to human health has been raised (30) but not yet rigorously investigated.

Furthermore, these data argue in favor of screening apparently healthy cattle after slaughter to investigate whether significant

levels of subclinical or preclinical BSE are present.

Secondly, because animals can harbor high levels of infectivity without developing clinical signs of prion disease, these results

argue that PrPSc and indeed prions (whether or not they are identical) may not themselves be highly neurotoxic. Such results are

in accordance with earlier findings of a lack of correlation between clinical disease and neuropathological features of prion disease

(31), prion diseases in which PrPSc is barely or not detectable (32-35), and studies in mice with reduced levels of PrPC expression

that have extremely high levels of PrPSc and prions in the brain and yet remain well for several months after their wild-type

counterparts succumb (36). Conversely, Tg20 mice, with high levels of PrPC, have short incubation periods and yet produce low

levels of PrPSc after inoculation with mouse prions (27). In addition, brain grafts producing high levels of PrPSc do not damage

adjacent tissue in PrP knockout (Prnpo/o) mice (37). The cause of neurodegeneration in prion diseases remains unclear. It remains

possible that prion neurodegeneration is related, at least in part, to loss of function of PrPC. That Prnpo/o mice (other than those

associated with overexpression of the Prnp-like gene Prnd; ref. 38) do not develop neurodegeneration could be caused by

compensatory adaptations during neurodevelopment. Complete or near complete ablation of PrP expression in an adult mouse

using conditional gene expression methods has not yet been achieved. An alternative hypothesis is that a toxic, possibly

infectious, intermediate is produced in the process of conversion of PrPC to PrPSc, with PrPSc, present as highly aggregated

material, being a relatively inert end-product. The steady-state level of such a toxic monomeric or oligomeric PrP intermediate then

could determine rate of neurodegeneration. One possibility is that Sc237-inoculated CD-1 mice propagate prions very slowly and

that such a toxic intermediate is generated at extremely low levels that are tolerated by the mouse. The fact that the PrPSc­negative

Sc237-inoculated CD-1 mice were the ones culled earlier than those that were PrPSc positive, allows the assumption that

they may have become PrPSc positive had they lived longer. A more detailed study of the time course of accumulation of infectivity

will be necessary to investigate this further.

Transmission of Infectivity from Subclinical Animals. The transmission properties of prions from the subclinical Sc237inoculated

CD-1 mice were remarkable. With respect to transmissions to additional CD-1 or Tg20 mice, the 100% attack rate and

highly consistent incubation periods suggest transmission in the absence of a barrier. However, the incubation periods, notably in

the Tg20 mice, which succumb to RML mouse prions in around 60 days (27), are very prolonged. The 100% attack rate argues

against this being a consequence of low prion titer in the inoculum. Incubation period at end point dilution in Tg20 mice of RML

mouse prions is around 109 days (37). Remarkably, passage in hamsters of this isolate also showed a 100% attack rate and

consistent incubation periods suggestive of transmission in the absence of a barrier. Again, incubation periods were extremely

prolonged and differed markedly from the transmission properties of Sc237/263K prions in hamsters (8, 10, 39). Indeed, the

incubation period seen would correspond to an Sc237 titer in Syrian hamsters of <103 LD50/g brain, which is completely

inconsistent with the titers measured; Sc237 incubation periods at end point dilution in Syrian hamsters are around 130 days (40).

That a 100% attack rate was seen at a 127-day incubation period argues against persistent Sc237 inoculum, rather than newly

formed prions, being responsible for the pathogenicity to hamsters. Together, these data suggested production of novel infectivity,

pathogenic for both mice and hamsters on passage of Sc237 to CD-1 mice.

A recent report has suggested that hamster scrapie (263K) may persist in the brains of inoculated C57BL/10 mice for prolonged

periods without replication (41). Our data are not consistent with infectivity in the PrPSc-positive Sc237-inoculated CD-1 mice

being the result of persistence of residual Sc237 hamster scrapie inoculum. High levels of mouse PrPSc (and no hamster PrPSc)

are detectable on Western blot, and prions pathogenic for mice are generated. Intracerebral inoculation is known to result in wide

distribution of the inoculum outside the brain via the circulation and, presumably as a result of other clearance mechanisms, brain

titers fall to undetectable levels within a few days (42). Prion titers present in the brains of these mice ( 108 LD50/g mouse brain

assayed in hamsters) considerably exceed those inoculated ( 8.5 × 106). Together, these data argue strongly for prion

replication in these mice. It is possible that the prions detected in the brains of the C57BL/10 mice in the earlier study were not

caused by persistence of inoculated 263K, but by propagation of prions with the properties we describe. The species origin of

PrPSc (hamster or mouse) in the 263K-inoculated C57BL/10 mice was not reported. The observation periods postinoculation were

generally much shorter than those we report here. That those mice with the longest survival postinoculation produced the shortest

incubation periods on passage of infectivity into hamsters is consistent with propagation, rather than simply persistence, of prions

in this earlier study (41).

9/13/2005

Page 5 of 17

Re-Evaluation of Species Barriers. Importantly, these data seriously question our current understanding of species barriers. The

assessment of species barriers has relied on the development of a clinical disease in inoculated animals. On this basis there is a

highly efficient barrier limiting transmission of Sc237 prions to mice. However, although not developing a clinical disease, and

indeed living as long as mock-inoculated mice, Sc237-inoculated mice may accumulate high levels of prions in their brains.

Previous studies on the species barrier between hamsters and mice (using the Sc237 or 263K strain) did not report whether PrPSc

and/or infectivity were present in clinically unaffected animals (8, 12) or have attempted passage from mice only up to 280 days

postinoculation (10). The barrier to primary passage appears in this case to be to the development of rapid neurodegeneration and

the resulting clinical syndrome rather than a barrier to prion propagation itself.

The transmission characteristics of prions generated in the brains of Sc237-inoculated CD-1 mice argue that one or more distinct

prion strains have been generated. The finding that Sc237-inoculated CD-1 mice in which PrPSc could not be detected on Western

blot were the ones that had been culled after shorter periods than mice with detectable PrPSc argues that prion propagation is

occurring in all of these mice, but is detectable only after prolonged incubation periods. That high levels of hamster infectivity were

present in the PrPSc-negative Sc237-inoculated CD-1 mouse (examined at 463 days postinoculation) in the absence of detectable

mouse infectivity, whereas very high and relatively comparable titers of both mouse and hamster infectivity were present in the

PrPSc-positive Sc237-inoculated CD-1 mouse (examined at 730 days postinoculation) suggests that more than one strain may be

propagating in these mice, with preferential replication of a strain with higher pathogenicity for hamsters early in the incubation

period. One possibility is that early replication of a prion strain pathogenic only for hamsters is induced in Sc237-inoculated CD-1

mice, then later followed by the generation of a second strain that is pathogenic for mice. More extensive passage studies,

including cloning of strains at end-point dilution in both mice and hamsters, will be required to investigate this further and to

characterize the strain(s) of prions generated in the brains of Sc237-inoculated CD-1 mice.

http://www.pnas.org/cgi/content/full/97/18/10248

Neurobiology of Disease

Subclinical Bovine Spongiform Encephalopathy Infection in

Transgenic Mice Expressing Porcine Prion Protein

Joaquín Castilla,1 Alfonso Gutiérrez-Adán,2 Alejandro Brun,1 Deirdre Doyle,3 Belén Pintado,2 Miguel A. Ramírez,2

Francisco J. Salguero,1 Beatriz Parra,1 Fayna Díaz San Segundo,1 José M. Sánchez-Vizcaíno,1 Mark Rogers,3 and

Juan M. Torres1

1Centro de Investigación en Sanidad Animal, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria, Valdeolmos,

28130 Madrid, Spain, 2Departamento de Reproducción Animal y Conservación de Recursos Zoogenéticos, 28040 Madrid, Spain,

and 3Department of Zoology and Conway Institute for Biomolecular and Biomedical Research, University College Dublin, Belfield,

Dublin 4, Ireland

Abstract

The bovine-porcine species barrier to bovine spongiform encephalopathy (BSE) infection was explored by generating transgenic But the main

mouse lines expressing the porcine prion protein (PrP) gene. All of the porcine transgenic (poTg) mice showed clinical signs of

BSE after intracerebral inoculation with a high-titer BSE inoculum. The protease-resistant PrP (PrPres) was detected in 14% (3 of

22) of the BSE-infected poTg mice by immunohistochemical or immunoblot analysis. Despite being able to infect 42% (5 of 12) of

control mice, a low-dose BSE inoculum failed to penetrate the species barrier in our poTg mouse model. The findings of these

infectivity studies suggest that there is a strong species barrier between cows and pigs. However, after second-passage infection

of poTg mice using brain homogenates of BSE-inoculated mice scoring negative for the incoming prion protein as inoculum, it was

9/13/2005

Page 6 of 17

possible to detect the presence of the infectious agent. Thus, porcine-adapted BSE inocula were efficient at infecting poTg mice,

giving rise to an incubation period substantially reduced from 300 to 177 d after inoculation and to the presence of PrPres in 100%

(21 of 21) of the mice. We were therefore able to conclude that initial exposure to the bovine prion may lead to subclinical infection

such that brain homogenates from poTg mice classified as uninfected on the basis of the absence of PrPres are infectious when

used to reinoculate poTg mice. Collectively, our findings suggest that these poTg mice could be used as a sensitive bioassay

model for prion detection in pigs.

snip...

Discussion

The transgenic mouse lines developed expressed the porcine PrP transgene at different levels. This is characteristic of random transgene integration in the mouse genome

by the microinjection technique. Given that high expression levels promote reduced incubation times for heterologous and homologous prion propagation in mice (Scott et

al., 1997b ; Castilla et al., 2003 ), we selected two poTg lines, poTg001 and poTg027, expressing fourfold and 16-fold, respectively, the levels of PrP protein found in pig

brain.

We observed that mice expressing higher levels of poPrP spontaneously developed clinical signs. A similar neurological syndrome was described previously by Westaway

et al. (1994 ) in older Tg PrP mice expressing high levels of hamster, ovine, or murine PrP transgenes. This phenomenon may be related to the observed toxicity of

overexpressed PrP in certain cell lines, which suggests that lack of physiological PrPC expression may render pathogenic in mice. However, the lifespan of poTg027 mice

was much longer than the time needed by porcine prions to propagate in these animals, and the confirmation of infection could be tested using proteinase K (PK)-resistant

studies. In none of the cases did the noninoculated animals presenting late clinical signs show PK-resistant protein.

We observed substantial evidence of subclinical BSE infection in our poTg mice. PoTg mice inoculated with BSE1 showed no clinical signs of BSE or detectable PrPres

protein. However, subsequent passage of brain homogenates from these mice indicated the high level of infectivity of one of these animals. The presence of subclinical

infection was particularly evident when we used the poTgBSE1-N2 inoculum (first-passage boTgBSE1 in poTg PrPres-negative mice), which led to a mean incubation time

of 269 d and to PrPres that was detectable by Western blotting in two of six mice. The presence of subclinical infection has been reported in other species (Race and

Chesebro, 1998 ; Hill et al., 2000 ). Although there is no evidence of clinical BSE disease in the domestic pig population, pigs are susceptible to BSE, and our

observations raise the possibility of subclinical infection occurring in pigs. The poTg model could be used as an assay for subclinical infection in suspected cases of prion

disease in pigs.

Three inocula (Fig. 3) were used to infect the poTg mice. These inocula are known to efficiently infect transgenic mice expressing the bovine PrP gene (boTg110 line)

(Castilla et al., 2003 ). We used the same vector to express the porcine and bovine PrP genes under the mouse PrP promoter. In the boTg110 model, increasing the

PrPres titer had no effect on the incubation time. When the low-dose BSE1 inoculum was tested in a normal mouse line, the animals showed neurological signs of disease,

and 5 of 12 (42%) scored positive for PrPres. These data indicate that the BSE1 inoculum can cross the bovine-murine species barrier, although the expression level of the

mouse PrPC is approximately half that shown by our transgenic lines.

However, the low-dose BSE1 inoculum provided evidence for a strong bovine-porcine species barrier, because it produced no signs of infection in the poTg001 or poTg027

mice. Survival times were unchanged compared with those observed in control PBS-inoculated poTg001 or poTg027 mice, and no PrPres was detected in any of the 39

inoculated mice (Table 1). In contrast, the higher titer BSE2 and boTgBSE1 inocula were able to breach the bovine-porcine species barrier, and PrPres was detected in 3 of

22 infected poTg mice (14%). Additional evidence for the bovine-porcine species barrier was obtained in second-passage transmission from BSE-infected poTg mice. The

survival time dropped from 488 to 198 d postinoculation (dpi) for poTg001 and from 300 to 177 dpi for the poTg027 mice. The presence of a strong barrier may explain the

resistance to infection shown by pigs during the BSE epidemic in the United Kingdom.

Contrary to the strong species barrier observed when poTg mice were inoculated with BSE, there was little evidence of a species barrier in the opposite direction (i.e., when

we infected boTg110 mice with poTgBSE1). All of the boTg mice infected with this inoculum scored positive for PrPres, suggesting that the barrier has different difficulty

levels depending on the direction of the infection. Western blotting analysis confirmed that the PrPres observed in the bo110Tg mice displayed the same pattern (band size,

glycoform ratio) as the boTgBSE1 or BSE1 inocula but a pattern that is different from that of the newly generated porcine prion (po027Tg) (Fig. 2C). A characteristic feature

of the BSE prion is that it retains its biological properties when transmitted to other species such as humans (Collinge and Rossor, 1996 ; Collinge et al., 1996 ; Will and

Zeidler, 1996 ; Scott et al., 1999 ), sheep (Foster et al., 1993 , 2001 ), or mice (Fraser et al., 1992 ; Lasmezas et al., 1997 ). Thus, the lack of a strong species

barrier observed for transmission in the direction of pig to cow might be explained if the initial BSE inoculum infecting the pig confers BSE-like properties on the porcine

prion, although the primary amino acid sequence of this prion is the porcine one. Alternatively, these results could be explained as follows: (1) the bovine PrP is a very

permissive protein, more easily transformed by other heterologous prions or (2) the new porcine prion is highly infectious compared with others. This second possibility will

be studied using other transgenic mice expressing ovine and human PrP.

The species barrier is related to amino acid sequence differences in the globular domain of the PrP protein, which undergoes a conformational change from -helix to ­pleated

sheet structures. The porcine PrP shows the most unique amino acid sequence (5) in this domain when compared with the mouse, cow, sheep, hamster, and

human PrP sequences. Figure 6 compares the globular domains of porcine, bovine, and mouse PrP. It may be observed that four of the five unique amino acids occur in

9/13/2005

Page 7 of 17

helix 3, and that there are two additional differences in this helix between the porcine and bovine sequence, I to V and R to K. The K residue is known to alter the length and

quality of definition of helix 3 (Calzolai et al., 2000 ), and it is possible that this combination of amino acid variants alters the structure of helix 3 sufficiently to inhibit

interactions between porcine PrPC and PrPres. Nuclear magnetic resonance analysis indicates that the global architecture of this region is similar for all species analyzed to

date (Riek et al., 1998 ; Lopez Garcia et al., 2000 ; Zahn et al., 2000 ), but individual amino acid changes have been shown to affect local conformation or surface

charge (Lopez Garcia et al., 2000 ). These subtle differences may be sufficient to strengthen or weaken a species barrier.

http://www.jneurosci.org/cgi/content/full/24/21/5063

British Medical Bulletin 66:161-170 (2003)

© 2003 The British Council

Subclinical prion infection in humans and animals

Andrew F Hill and John Collinge

MRC Prion Unit, Department of Neurodegenerative Disease, Institute of Neurology, London, UK

Transmission of prion diseases between mammalian species is limited by a so-called ‘species’ or ‘transmission’ barrier. Recognition of prion transmission usually relies on

the appearance of clinical symptoms in inoculated animals and the interval between inoculation and appearance of clinical disease is designated incubation period. At some

point during this clinically silent period, neuropathological and biochemical changes as well as accumulation of prions in the brain can be detected and this stage can be

called preclinical prion disease. Recently, several lines of evidence have suggested that subclinical forms of prion disease exist, in which high levels of infectivity and

PrPSc are found in animals that do not develop clinically apparent disease during a normal life-span. Such asymptomatic prion ‘carrier’ states challenge our current

understanding of pathogenesis as well as of the molecular basis of barriers to transmission. Subclinical as well as preclinical/clinical prion disease may be relevant when

analysing the risk to public health of potential sources of prion exposure.

http://bmb.oxfordjournals.org/cgi/content/abstract/66/1/161

Journal of Virology, July 2003, p. 7991-7998, Vol. 77, No. 14

0022-538X/03/$08.00+0 DOI: 10.1128/JVI.77.14.7991-7998.2003

Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Subclinical Prion Disease Induced by Oral Inoculation

Alana M. Thackray,1 Michael A. Klein,2 and Raymond Bujdoso1*

Department of Clinical Veterinary Medicine, Centre for Veterinary Science, University of Cambridge, Cambridge, United Kingdom CB3 OES,1 Prion Research Group,

Institute of Virology and Immunobiology, University of Würzburg, D-97078 Würzburg, Germany2

Received 9 January 2003/ Accepted 30 April 2003

Natural transmission of prion disease is believed to occur by peripheral infection such as oral inoculation. Following this route of inoculation, both the peripheral nervous

system and the lymphoreticular system may be involved in the subsequent neuroinvasion of the central nervous system by prions, which may not necessarily result in

clinical signs of terminal disease. Subclinical prion disease, characterized by the presence of infectivity and PrPSc in the absence of overt clinical signs, may occur. It is not

known which host factors contribute to whether infection with prions culminates in a terminal or subclinical disease state. We have investigated whether the level of host

PrPc protein expression is a factor in the development of subclinical prion disease. When RML prion inoculum was inoculated by either the i.c. or intraperitoneal route, wildtype

and tga20 mice both succumbed to terminal prion disease. In contrast, orally inoculated tga20 mice succumbed to terminal prion disease, whereas wild-type mice

showed no clinical signs. However, wild-type mice sacrificed 375 or 525 days after oral inoculation harbored significant levels of brain PrPSc and infectivity. These data

show that same-species transmission of prions by the oral route in animals that express normal levels of PrPc can result in subclinical prion disease. This indicates that the

level of host PrPc protein expression is a contributing factor to the regulation of development of terminal prion disease. Events that increase PrPc expression may

predispose a prion-infected animal to the more deleterious effects of prion pathology.

* Corresponding author. Mailing address: Centre for Veterinary Science, Department of Clinical Veterinary Medicine, University of Cambridge, Madingley Rd., Cambridge,

United Kingdom CB3 OES. Phone: 44-1223-337655. Fax: 44-1223-337610. E-mail: [email protected] .

9/13/2005

Page 8 of 17

Journal of Virology, July 2003, p. 7991-7998, Vol. 77, No. 14

0022-538X/03/$08.00+0 DOI: 10.1128/JVI.77.14.7991-7998.2003

http://jvi.asm.org/cgi/content/abstract/77/14/7991

Journal of Virology, March 2002, p. 2510-2517, Vol. 76, No. 5

0022-538X/02/$04.00+0 DOI: 10.1128/jvi.76.5.2510-2517.2002

Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Chronic Subclinical Prion Disease Induced by Low-Dose Inoculum

*** Alana M. Thackray,1 Michael A. Klein,2 Adriano Aguzzi,3 and Raymond Bujdoso1*

Centre for Veterinary Science, Department of Clinical Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, United Kingdom,1 University Hospital Basel,

Institute of Pathology, CH-4003 Basel,2 Institute of Neuropathology, University Hospital of Zürich, CH-8091 Zürich, Switzerland3

Received 24 September 2001/ Accepted 16 November 2001

We have compared the transmission characteristics of the two mouse-adapted scrapie isolates, ME7 and Rocky Mountain Laboratory (RML), in tga20 mice. These mice

express elevated levels of PrP protein compared to wild-type mice and display a relatively short disease incubation period following intracerebral prion inoculation. Terminal

prion disease in tga20 mice induced by ME7 or RML was characterized by a distinct pattern of clinical signs and different incubation times. High-dose RML inoculated

intracerebrally into tga20 mice induced the most rapid onset of clinical signs, with mice succumbing to terminal disease after only 58 ± 3 days. In contrast, high-dose ME7

gave a mean time to terminal disease of 74 ± 0 days. Histological examination of brain sections from prion-inoculated tga20 mice at terminal disease showed that ME7 gave

rise to a more general and extensive pattern of vacuolation than RML. Low-dose inoculum failed to induce terminal disease but did cause preclinical symptoms, including

the appearance of reversible clinical signs. Some mice oscillated between showing no clinical signs and early clinical signs for many months but never progressed to

terminal disease. Brain tissue from these mice with chronic subclinical prion disease, sacrificed at >200 days postinoculation, contained high levels of infectivity and showed

the presence of PrPSc. Parallel analysis of brain tissue from mice with terminal disease showed similar levels of infectivity and detectable PrPSc. These results show that

high levels of infectivity and the presence of the abnormal isomer of PrP can be detected in mice with subclinical disease following low-dose prion inoculation.

* Corresponding author. Mailing address: Centre for Veterinary Science, Department of Clinical Veterinary Medicine, University of Cambridge, Madingley Rd., Cambridge

CB3 0ES, United Kingdom. Phone: 44-1223-337655. Fax: 44-1223-337610. E-mail: [email protected] .

Journal of Virology, March 2002, p. 2510-2517, Vol. 76, No. 5

0022-538X/02/$04.00+0 DOI: 10.1128/jvi.76.5.2510-2517.2002

http://jvi.asm.org/cgi/content/abstract/76/5/2510

Journal of Virology, November 2001, p. 10106-10112, Vol. 75, No. 21

0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.21.10106-10112.2001

Long-Term Subclinical Carrier State Precedes Scrapie Replication and Adaptation in a

Resistant Species: Analogies to Bovine Spongiform Encephalopathy and Variant

Creutzfeldt-Jakob Disease in Humans

Richard Race, Anne Raines, Gregory J. Raymond, Byron Caughey, and Bruce Chesebro*

Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, Hamilton, Montana 59840

Received 24 May 2001/Accepted 31 July 2001

9/13/2005

Page 9 of 17

Cattle infected with bovine spongiform encephalopathy (BSE) appear to be a reservoir for transmission of variant Creutzfeldt-Jakob disease (vCJD) to humans. Although just

over 100 people have developed clinical vCJD, millions have probably been exposed to the infectivity by consumption of BSE-infected beef. It is currently not known

whether some of these individuals will develop disease themselves or act as asymptomatic carriers of infectivity which might infect others in the future. We have studied

agent persistence and adaptation after cross-species infection using a model of mice inoculated with hamster scrapie strain 263K. Although mice inoculated with hamster

scrapie do not develop clinical disease after inoculation with 10 million hamster infectious doses, hamster scrapie infectivity persists in brain and spleen for the life span of

the mice. In the present study, we were surprised to find a 1-year period postinfection with hamster scrapie where there was no evidence for replication of infectivity in

mouse brain. In contrast, this period of inactive persistence was followed by a period of active replication of infectivity as well as adaptation of new strains of agent capable

of causing disease in mice. In most mice, neither the early persistent phase nor the later replicative phase could be detected by immunoblot assay for protease-resistant

prion protein (PrP). If similar asymptomatic carriers of infection arise after exposure of humans or animals to BSE, this could markedly increase the danger of additional

spread of BSE or vCJD infection by contaminated blood, surgical instruments, or meat. If such subclinical carriers were negative for protease-resistant PrP, similar to our

mice, then the recently proposed screening of brain, tonsils, or other tissues of animals and humans by present methods such as immunoblotting or immunohistochemistry

might be too insensitive to identify these individuals.

* Corresponding author. Mailing address: Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, 903 South Fourth St., Hamilton, MT 59840-2999. Phone:

(406) 363-9354. Fax: (406) 363-9286. E-mail: [email protected] .

Journal of Virology, November 2001, p. 10106-10112, Vol. 75, No. 21

0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.21.10106-10112.2001

http://jvi.asm.org/cgi/content/abstract/75/21/10106

From: TSS ()

Subject: PrPSc distribution of a natural case of bovine spongiform encephalopathy

Date: August 8, 2005 at 12:28 pm PST

PrPSc distribution of a natural case of bovine

spongiform encephalopathy

Yoshifumi Iwamaru, Yuka Okubo, Tamako Ikeda, Hiroko Hayashi, Mori-

kazu Imamura, Takashi Yokoyama and Morikazu Shinagawa

Priori Disease Research Center, National Institute of Animal Health, 3-1-5

Kannondai, Tsukuba 305-0856 Japan [email protected]

Abstract

Bovine spongiform encephalopathy (BSE) is a disease of cattle that causes

progressive neurodegeneration of the central nervous system. Infectivity

of BSE agent is accompanied with an abnormal isoform of prion protein

(PrPSc).

The specified risk materials (SRM) are tissues potentially carrying BSE

infectivity. The following tissues are designated as SRM in Japan: the

skull including the brain and eyes but excluding the glossa and the masse-

ter muscle, the vertebral column excluding the vertebrae of the tail, spinal

cord, distal illeum. For a risk management step, the use of SRM in both

animal feed or human food has been prohibited. However, detailed

PrPSc distribution remains obscure in BSE cattle and it has caused controversies

about definitions of SRM. Therefore we have examined PrPSc

distribution in a BSE cattle by Western blotting to reassess definitions of

SRM.

The 11th BSE case in Japan was detected in fallen stock surveillance.

The carcass was stocked in the refrigerator. For the detection of PrPSc,

200 mg of tissue samples were homogenized. Following collagenase

treatment, samples were digested with proteinase K. After digestion,

PrPSc was precipitated by sodium phosphotungstate (PTA). The pellets

were subjected to Western blotting using the standard procedure.

Anti-prion protein monoclonal antibody (mAb) T2 conjugated horseradish

peroxidase was used for the detection of PrPSc.

PrPSc was detected in brain, spinal cord, dorsal root ganglia, trigeminal

ganglia, sublingual ganglion, retina. In addition, PrPSc was also detected

in the peripheral nerves (sciatic nerve, tibial nerve, vagus nerve).

Our results suggest that the currently accepted definitions of SRM in

9/13/2005

179

Page 10 of 17

BSE cattle may need to be reexamined.

T. Kitamoto (Ed.)

PRIONS

Food and Drug Safety

================

ALSO from the International Symposium of Prion Diseases held in Sendai, October 31, to

November 2, 2004;

Bovine spongiform encephalopathy (BSE) in Japan

snip...

"Furthermore, current studies into transmission of cases of BSE that are

atypical or that develop in young cattle are expected to amplify the BSE

prion"

NO. Date conf. Farm Birth place and Date Age at diagnosis

8. 2003.10.6. Fukushima Tochigi 2001.10.13. 23

9. 2003.11.4. Hiroshima Hyogo 2002.1.13. 21

Test results

# 8b, 9c cows Elisa Positive, WB Positive, IHC negative, histopathology

negative

b = atypical BSE case

c = case of BSE in a young animal

b,c, No PrPSc on IHC, and no spongiform change on histology

International Symposium of Prion Diseases held in Sendai, October 31, to

November 2, 2004.

Tetsuyuki Kitamoto

Professor and Chairman

Department of Prion Research

Tohoku University School of Medicine

2-1 SeiryoAoba-ku, Sendai 980-8575, JAPAN

TEL +81-22-717-8147 FAX +81-22-717-8148

e-mail; [email protected]

Symposium Secretariat

Kyomi Sasaki

TEL +81-22-717-8233 FAX +81-22-717-7656

e-mail: [email protected]

=================================

9/13/2005

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Page 11 of 17

From: TSS ()

Subject: Atypical Proteinase K-Resistant Prion Protein (PrPres) observed in an Apparently Healthy 23-Month-Old Holstein Steer

Date: August 26, 2005 at 10:24 am PST

Atypical Proteinase K-Resistant Prion Protein (PrPres) observed in an Apparently Healthy 23-Month-Old Holstein Steer

Jpn. J. Infect. Dis., 56, 221-222, 2003

Laboratory and Epidemiology Communications

Atypical Proteinase K-Resistant Prion Protein (PrPres) Observed in an Apparently Healthy 23-Month-Old Holstein Steer

Yoshio Yamakawa*, KenÕichi Hagiwara, Kyoko Nohtomi, Yuko Nakamura, Masahiro Nishizima ,Yoshimi Higuchi1, Yuko Sato1, Tetsutaro Sata1 and the Expert Committee

for BSE Diagnosis, Ministry of Health, Labour and Welfare of Japan2

Department of Biochemistry & Cell Biology and 1Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640 and 2Miistry of Health, Labour and

Welfare, Tokyo 100-8916

Communicated by Tetsutaro Sata

(Accepted December 2, 2003)

*Corresponding author: Mailing address: Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Toyama 1-23-1, Shinjuku-ku, Tokyo 1628640,

Japan. Tel: +81-3-5285-1111, Fax: +81-3-5285-1157, E-mail: [email protected]

Since October 18, 2001, 'bovine spongiform encephalopathy (BSE) examination for all cattle slaughtered at abattoirs in the country' has been mandated in Japan by the

Ministry of Health, Labour and Welfare (MHLW). 'Plateria' ELISA-kit (Bio-Rad Laboratories, Hercules, Calif., USA) is routinely used at abattoirs for detecting proteinase K

(PK)-resistant prion protein (PrPSc) in the obex region. Samples positive according to the ELISA screening are further subjected to Western blot (WB) and histologic and

immunohistochemical examination (IHC) at the National Institute of Infectious Diseases (NIID) or Obihiro University. If PrPSc is detected either by WB or by IHC, the cattle

are diagnosed as BSE. The diagnosis is approved by the Expert Committee for BSE Diagnosis, MHLW. From October 18, 2001 to September 30, 2003, approximately 2.5

million cattle were screened at abattoirs. A hundred and te
 

flounder

Well-known member
Joined
Sep 3, 2005
Messages
2,631
Reaction score
0
Location
TEXAS
From: TSS ()

Subject: PrPSc distribution of a natural case of bovine spongiform encephalopathy

Date: August 8, 2005 at 12:28 pm PST

PrPSc distribution of a natural case of bovine

spongiform encephalopathy

Yoshifumi Iwamaru, Yuka Okubo, Tamako Ikeda, Hiroko Hayashi, Mori-

kazu Imamura, Takashi Yokoyama and Morikazu Shinagawa

Priori Disease Research Center, National Institute of Animal Health, 3-1-5

Kannondai, Tsukuba 305-0856 Japan [email protected]

Abstract

Bovine spongiform encephalopathy (BSE) is a disease of cattle that causes

progressive neurodegeneration of the central nervous system. Infectivity

of BSE agent is accompanied with an abnormal isoform of prion protein

(PrPSc).

The specified risk materials (SRM) are tissues potentially carrying BSE

infectivity. The following tissues are designated as SRM in Japan: the

skull including the brain and eyes but excluding the glossa and the masse-

ter muscle, the vertebral column excluding the vertebrae of the tail, spinal

cord, distal illeum. For a risk management step, the use of SRM in both

animal feed or human food has been prohibited. However, detailed

PrPSc distribution remains obscure in BSE cattle and it has caused controversies

about definitions of SRM. Therefore we have examined PrPSc

distribution in a BSE cattle by Western blotting to reassess definitions of

SRM.

The 11th BSE case in Japan was detected in fallen stock surveillance.

The carcass was stocked in the refrigerator. For the detection of PrPSc,

200 mg of tissue samples were homogenized. Following collagenase

treatment, samples were digested with proteinase K. After digestion,

PrPSc was precipitated by sodium phosphotungstate (PTA). The pellets

were subjected to Western blotting using the standard procedure.

Anti-prion protein monoclonal antibody (mAb) T2 conjugated horseradish

peroxidase was used for the detection of PrPSc.

PrPSc was detected in brain, spinal cord, dorsal root ganglia, trigeminal

ganglia, sublingual ganglion, retina. In addition, PrPSc was also detected

in the peripheral nerves (sciatic nerve, tibial nerve, vagus nerve).

Our results suggest that the currently accepted definitions of SRM in

9/13/2005

179

Page 10 of 17

BSE cattle may need to be reexamined.

T. Kitamoto (Ed.)

PRIONS

Food and Drug Safety

================

ALSO from the International Symposium of Prion Diseases held in Sendai, October 31, to

November 2, 2004;

Bovine spongiform encephalopathy (BSE) in Japan

snip...

"Furthermore, current studies into transmission of cases of BSE that are

atypical or that develop in young cattle are expected to amplify the BSE

prion"

NO. Date conf. Farm Birth place and Date Age at diagnosis

8. 2003.10.6. Fukushima Tochigi 2001.10.13. 23

9. 2003.11.4. Hiroshima Hyogo 2002.1.13. 21

Test results

# 8b, 9c cows Elisa Positive, WB Positive, IHC negative, histopathology

negative

b = atypical BSE case

c = case of BSE in a young animal

b,c, No PrPSc on IHC, and no spongiform change on histology

International Symposium of Prion Diseases held in Sendai, October 31, to

November 2, 2004.

Tetsuyuki Kitamoto

Professor and Chairman

Department of Prion Research

Tohoku University School of Medicine

2-1 SeiryoAoba-ku, Sendai 980-8575, JAPAN

TEL +81-22-717-8147 FAX +81-22-717-8148

e-mail; [email protected]

Symposium Secretariat

Kyomi Sasaki

TEL +81-22-717-8233 FAX +81-22-717-7656

e-mail: [email protected]

=================================

9/13/2005

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Page 11 of 17

From: TSS ()

Subject: Atypical Proteinase K-Resistant Prion Protein (PrPres) observed in an Apparently Healthy 23-Month-Old Holstein Steer

Date: August 26, 2005 at 10:24 am PST

Atypical Proteinase K-Resistant Prion Protein (PrPres) observed in an Apparently Healthy 23-Month-Old Holstein Steer

Jpn. J. Infect. Dis., 56, 221-222, 2003

Laboratory and Epidemiology Communications

Atypical Proteinase K-Resistant Prion Protein (PrPres) Observed in an Apparently Healthy 23-Month-Old Holstein Steer

Yoshio Yamakawa*, KenÕichi Hagiwara, Kyoko Nohtomi, Yuko Nakamura, Masahiro Nishizima ,Yoshimi Higuchi1, Yuko Sato1, Tetsutaro Sata1 and the Expert Committee

for BSE Diagnosis, Ministry of Health, Labour and Welfare of Japan2

Department of Biochemistry & Cell Biology and 1Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640 and 2Miistry of Health, Labour and

Welfare, Tokyo 100-8916

Communicated by Tetsutaro Sata

(Accepted December 2, 2003)

*Corresponding author: Mailing address: Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Toyama 1-23-1, Shinjuku-ku, Tokyo 1628640,

Japan. Tel: +81-3-5285-1111, Fax: +81-3-5285-1157, E-mail: [email protected]

Since October 18, 2001, 'bovine spongiform encephalopathy (BSE) examination for all cattle slaughtered at abattoirs in the country' has been mandated in Japan by the

Ministry of Health, Labour and Welfare (MHLW). 'Plateria' ELISA-kit (Bio-Rad Laboratories, Hercules, Calif., USA) is routinely used at abattoirs for detecting proteinase K

(PK)-resistant prion protein (PrPSc) in the obex region. Samples positive according to the ELISA screening are further subjected to Western blot (WB) and histologic and

immunohistochemical examination (IHC) at the National Institute of Infectious Diseases (NIID) or Obihiro University. If PrPSc is detected either by WB or by IHC, the cattle

are diagnosed as BSE. The diagnosis is approved by the Expert Committee for BSE Diagnosis, MHLW. From October 18, 2001 to September 30, 2003, approximately 2.5

million cattle were screened at abattoirs. A hundred and ten specimens positive according to ELISA were subjected to WB/IHC. Seven showed positive by both WB and

IHC, all exhibiting the typical electrophoretic profile of a high content of the di-glycosylated molecular form of PrPSc (1-3) and the distinctive granular deposition of PrPSc in

neuronal cells and neuropil of the dorsal nucleus of vagus.

An ELISA-positive specimen from a 23 month-old Holstein steer slaughtered on September 29, 2003, in Ibaraki Prefecture (Ibaraki case) was sent to the NIID for

confirmation. The animal was reportedly healthy before slaughter. The OD titer in ELISA was slightly higher than the 'cut-off' level given by the manufacturer. The histology

showed no spongiform changes and IHC revealed no signal of PrPSc accumulation typical for BSE. However, WB analysis of the homogenate that was prepared from the

obex region and used for ELISA revealed a small amount of PrPSc with an electrophoretic profile different from that of typical BSE-associated PrPSc (1-3). The

characteristics were (i) low content of the di-glycosylated molecular form of PrPSc, (ii) a faster migration of the non-glycosylated form of PrPSc on SDS-PAGE, and (iii) less

resistance against PK digestion as compared with an authentic PrPSc specimen derived from an 83-month-old Holstein (Wakayama case) (Fig. 1). Table 1 summarizes the

relative amounts of three distinctive glycoforms (di-, mono, non-glycosylated) of PrPSc calculated by densitometric analysis of the blot shown in Fig. 1. As 2.5 mg wet weight

obex-equivalent homogenate of the Ibaraki case (Fig. 1, lane 4) gave slightly stronger band intensities of PrPSc than an 8 mg wet weight obex-equivqlent homogenate of a

typical BSE-affected Wakayama case (Fig. 1, lane 2), the amount of PrPSc accumulated in the Ibaraki case was calculated to be 1/500 - 1/1000 of the Wakayama case. In

the Ibaraki case, the PrPSc bands were not detectable in the homogenates of the proximal surrounding region of the obex. These findings were consistent with the low OD

value in ELISA, i.e., 0.2 - 0.3 for the Ibaraki case versus over 3.0 for the Wakayama case. The DNA sequence of the PrP coding region of the Ibaraki case was the same as

that appearing in the database (GenBank accession number: AJ298878). More recently, we encountered another case that resembled the Ibaraki case. It was a 21-monthold

Holstein steer from Hiroshima Prefecture. WB showed typical BSE-specific PrPSc deposition though IHC did not detect positive signals of PrPSc (data not shown).

Though the clinical onset of BSE is usually at around 5 years of age or later, a 20-month-old case showing the clinical signs has been reported (4). Variant forms of BSE

similar to our cases, i.e., with atypical histopathological and/or biochemical phenotype, have been recently reported in Italy (5) and in France (6). Such variant BSE was not

associated with mutations in the prion protein (PrP) coding region as in our case (5,6).

The Ministry of Agriculture, Forestry and Fisheries of Japan (MAFF) announced a ban of feeding ruminants with meat bone meal (MBM) on September 18, 2001, and a

complete ban was made on October 15 of the same year. According to the recent MAFF report, the previous seven cases of BSE in Japan were cattle born in 1995 - 1996

and possibly fed with cross-contaminated feed. However, the two cattle in this report were born after the complete ban. Whether contaminated MBM was implicated in the

present cases remains to be investigated.

REFERENCES

Collinge, J., Sidle, K. C. L., Meads, J., Ironside, J. and Hill, A. F. (1996): Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature, 383, 685690.

Bruce, M. E., Will, R. G., Ironside, J. W., McConnell, I., Drummond, D., Suttie, A., McCardle, L., Chree, A., Hope, J., Birkett, C., Cousens, S., Fraser, H. and Bostock, C. J.

(1997): Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature, 389, 498-501.

Hill, A. F., Desbruslais, M., Joiner, S., Sidle, K. C. L., Gowland, I. and Collinge, J. (1997): The same prion strain causes vCJD and BSE. Nature, 389, 448-450.

Matravers, W., Bridgeman, J. and Smith, M.-F. (ed.)(2000): The BSE Inquiry. p. 37. vol. 16. The Stationery Office Ltd., Norwich, UK.

Casalone, C., Zanusso, G., Acutis, P. L., Crescio, M. I., Corona, C., Ferrari, S., Capobianco, R., Tagliavini, F., Monaco, S. and Caramelli, M. (2003): Identification of a novel

molecular and neuropathological BSE phenotype in Italy. International Conference on Prion Disease: from basic research to intervention concepts. Gasreig, Munhen,

October 8-10.

Bicaba, A. G., Laplanche, J. L., Ryder, S. and Baron, T. (2003): A molecular variant of bovine spongiform encephalopatie. International Conference on Prion Disease: from

basic research to intervention concepts. Gasreig, Munhen, October 8-10.

Asante, E. A., Linehan, J. M., Desbruslais, M., Joiner, S., Gowland, I., Wood, A. L., Welch, J., Hill, A. F., Lloyd, S. E., Wadsworth, J. D. F. and Collinge, J. (2002). BSE

prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. EMBO J., 21, 6358-6366.

9/13/2005

Page 12 of 17

SEE SLIDES IN PDF FILE;

http://www.nih.go.jp/JJID/56/221.pdf

IN fact, we are now finding that as little as 1 mg (or 0.001 gm) caused 7% (1 of 14) of the cows to come down with BSE ;

Published online

January 27, 2005

Risk of oral infection with bovine spongiform

encephalopathy agent in primates

Corinne Ida Lasmézas, Emmanuel Comoy, Stephen Hawkins, Christian Herzog, Franck Mouthon, Timm Konold, Frédéric Auvré, Evelyne Correia,

Nathalie Lescoutra-Etchegaray, Nicole Salès, Gerald Wells, Paul Brown, Jean-Philippe Deslys

The uncertain extent of human exposure to bovine spongiform encephalopathy (BSE)—which can lead to variant

Creutzfeldt-Jakob disease (vCJD)—is compounded by incomplete knowledge about the ef.ciency of oral infection

and the magnitude of any bovine-to-human biological barrier to transmission. We therefore investigated oral

transmission of BSE to non-human primates. We gave two macaques a 5 g oral dose of brain homogenate from a

BSE-infected cow. One macaque developed vCJD-like neurological disease 60 months after exposure, whereas the

other remained free of disease at 76 months. On the basis of these .ndings and data from other studies, we made a

preliminary estimate of the food exposure risk for man, which provides additional assurance that existing public

health measures can prevent transmission of BSE to man.

snip...

BSE bovine brain inoculum

100 g 10 g 5 g 1 g 100 mg 10 mg 1 mg 0·1 mg 0·01 mg

Primate (oral route)* 1/2 (50%)

Cattle (oral route)* 10/10 (100%) 7/9 (78%) 7/10 (70%) 3/15 (20%) 1/15 (7%) 1/15 (7%)

RIII mice (ic. ip route)* 17/18 (94%) 15/17 (88%) 1/14 (7%)

PrPres biochemical detection . . .

The comparison is made on the basis of calibration of the bovine inoculum used in our study with primates against a bovine brain inoculum with a similar PrPres

concentration that was

inoculated into mice and cattle.8 *Data are number of animals positive/number of animals surviving at the time of clinical onset of disease in the .rst positive animal (%). The

accuracy of

. bioassays is generally judged to be about plus or minus 1 log. ic ip=intracerebral and intraperitoneal.

Table 1: Comparison of transmission rates in primates and cattle infected orally with similar BSE brain inocula

snip...end

www.thelancet.com Published online January 27, 2005

The BSE Inquiry / Statement No. 14. Issued 20 March 1998 ... number of feed

compounders and it became clear that cross contamination of feeds could occur. ...

9/13/2005

Page 13 of 17

http://www.bseinquiry.gov.uk/files/ws/s014.pdf

[PDF] The BSE Inquiry / Statement No 76F (Supplementary) Mr Alan ...

but the main problem was probably cross-contamination. ...

http://www.bseinquiry.gov.uk/files/ws/s076f.pdf

03-025IF 03-025IF-631 Linda A. Detwiler [PDF]

http://www.fsis.usda.gov/OPPDE/Comments/03-025IF/03-025IF-631.pdf

Specified Risk Materials (SRMs)

I am in full support of the interim final rule which prohibits SRMs from

being included in food for human consumption. In addition to the list of

tissues published in this rule, I am requesting that additional tissues be

added to the list. These would include dura

("sheath") covering the spinal cord and the ENTIRE INTESTINE (from pylorus

to rectum). The scientific justification is provided below. THESE SRMs

should also be prohibited from ANY FDA regulated food or product intended

for human consumption, including but not limited to flavorings, extracts,

etc. ...

Dr. Linda Detwiler comments in full;

http://www.fsis.usda.gov/OPPDE/Comments/03-025IF/03-025IF-634.pdf

NEW STRAIN OF TSE USA CATTLE OR JUST INCOMPETENCE IN TESTING???

DR. CLIFFORD: "Basically the IHC test, besides looking at location of the brain stem you're also doing a staining technique to identify abnormal prion proteins. In this case

they had some staining, but the staining did not match up with what they would typically see in a BSE case. It didn't have the normal distribution it would see within the

samples. So basically that's why the request for doing additional testing, and that's why we're sending it to Weybridge as well."

DR. CLIFFORD: "There was some staining present. But it did not match a normal pattern, and we're taking through that to do additional tests in additional parts of the brain

stem to try to see if we can find a normal staining pattern as well as sending that sample to Weybridge to run against their IHC."

http://www.usda.gov/wps/portal/usdahome?contentidonly=true&contentid=2005/07/0280.xml

IN CONFIDENCE

PERCEPTION OF UNCONVENTENTIONAL SLOW VIRUS DISEASES OF ANIMALS IN THE USA

1985 The Stetsonville outbreak (farmer's name: Brecke). In addition to the downer cows and horses Brecke's mink recieved a cereal supplement. Hartsough's view was that

this would contain bone meal and would be from a commercial source. If this were so and it was contaminated with a TME agent why were no other ranches affected?

Many mink ranches now feed a commerical pelleted diet. Brecke was equipped to process LARGE CARCASSES USING A CRUSHER/MIXER WHICH COULD

ACCOMMODATE A WHOLE COW!

snip...

Dead mink go for rendering but are used only in poultry feed.

A commercial mink ranch was visited. This was Johny Werth's, Capitol Fur Farm comprising 1400 breeding females. The feed is bought in from a commercial supplier in the

form of frozen packs of ''poultry'', ''fish'', ''dried egg'' or ''tripe''. A commercial mink cereal supplement is used and contains ''animal meat meal'' which was said to contain

material mainly from poultry or fish origin but OCCASIONALLY FROM BEEF SOURCES. the partially thawed packs were tipped into an augur mixer which has a fully loaded

capacity of 6000lb and this would be approximately 15000 mink per day.

In the fall at pelting time the skinned carcasses of the mink are placed in large barrels which are left in the open to freeze. When full, a renderer collects ''for use in poultry

feeds''.

Sections from the brains of the two Brecke TME inoculated cattle were examined and Marsh provided all the blocks from the 2nd steer for study at CVL and comparison with

BSE. In general the vacuolar changes were more severe than in most cases of BSE but very similar in distribution. Unfortunately material aken fro histopathology from those

anials omitted representaion of most of the brain stem. ...........

9/13/2005

Page 14 of 17

Wilbur Clarke (reference the Mission, Texas scrapie transmission transmission to cattle study) is now the State Veterinarian for Montana based at Helena.

I was given confidential access to sections from the Clarke scrapie-cattle transmission experiment. Details of the experimental design were as supplied previously by Dr.

Wrathall (copy of relevant information appended). Only 3 animals (2 inoculated with 2nd pass Suffolk scrapie and 1 inoculated with Angora goat passaged scrapie) showed

clinical signs. Clinical signs were characterised by weakness, ''a stilted hindlimb gait'', disorientation, ataxia and, terminally, lateral recumbency. The two cattle from which I

examined material were inocluated at 8 months of age and developed signs 36 months pi (goat scrapie inoculum) and 49 months pi (one of the Suffolk scrapie inoculated)

respectively. This latter animal was killed at 58 months of age and so the clinical duration was only 1 month. The neuropathology was somewhat different from BSE or the

Stetsonville TME in cattle. Vacuolar changes were minimal, to the extent that detection REQUIRED CAREFUL SEARCHING. Conversely astrocyte hypertrophy was a

widespread and prominent feature. The material requires DETAILED NEUROPATHOLOGICAL ASSESSMENT BUT WHETHER OR NOT THIS WILL BE DONE REMAINS

A QUESTION.

Transmission Studies

Mule deer transmissions of CWD were by intracerebral inoculation and compared with natural cases

{the following was written but with a single line marked through it ''first passage (by this route)}...TSS

resulted in a more rapidly progressive clinical disease with repeated episodes of synocopy ending in coma. One control animal became affected, it is believed through

contamination of inoculum (?saline). Further CWD transmissions were carried out by Dick Marsh into ferret, mink and squirrel monkey. Transmission occurred in ALL of

these species with the shortest

incubation period in the ferret.

snip...

Appendix 3

VISIT TO USA - DR A E WRATHALL - INFO OH BSE AND SCRAPIE

1. Dr Clark lately of the Scrapie Research Unit, Mission Texas has

successfully transmitted ovine and caprine scrapie to cattle. The

experimental results have not been published but there are plans to do

this. This work was initiated in 1978. A summary of it is:-

Expt A

6 Her x Jer calves born in 1978 were inoculated as follows with

a 2nd Suffolk scrapie passage:-

i/c 1ml; i/m, 5ml; s/c 5ml; oral 30ml.

1/6 went down after 48 months with a scrapie/BSE-like disease.

Expt B

6 Her or Jer or HxJ calves were inoculated with angora Goat

virus 2/6 went down similarly after 36 months.

Expt C

Mice inoculated from brains of calves/cattle in expts A • B

were resistant, only 1/20 going down with scrapie and this was the

reason given for not publishing.

Diagnosis in A, B, C was by histopath. No reports on SAT were given.

2. Dr Warren Foote indicated success so far in eliminating scrapie in

offspring from experimentally- (and naturally) infected sheep by ET.

He had found difficulty in obtaining embryos from naturally infected

sheep (cf SPA).

3. Prof. A Robertson gave a brief account of BSE. The US approach was to

accord it a very low profile indeed. Dr A Thiermann showed the

picture in the "Independent" with cattle being incinerated and thought

this was a fanatical incident to be avoided in the US at all costs.

BSE was not reported in USA.

4. Scrapie incidents (ie affected flocks) have shown a dramatic increase

since 1978. In 1953 when the National Control Scheme was started

there were 10-14 incidents, in 1978 - 1 and in 1988 so far 60.

5. Scrapie agent was reported to have been isolated from a solitary

fetus.

6. A western blotting diagnostic technique (? on PrP) shows some promise.

7. Results of a questionnaire sent to 33 states on the subject of the

national sheep scrapie programme survey indicated

17/33 wished to drop it

6/33 wished to develop it

9/13/2005

33

Page 15 of 17

8/33 had few sheep and were neutral

Information obtained from Dr Wrathall's notes of a meeting of the U.S.

Animal Health Association at Little Rock, Arkansas Nov. 1988.

end...TSS

>> Differences in tissue distribution could require new regulations

>> regarding specific risk material (SRM) removal.

snip...end

full text 33 PAGES ;

http://www.bseinquiry.gov.uk/files/mb/m11b/tab01.pdf

http://www.bseinquiry.gov.uk/files/yb/1988/10/00001001.pdf

It was, however, performed in the USA in 1979, when it was shown that cattle inoculated with the scrapie agent endemic in the flock of Suffolk sheep at the United States

Department of Agriculture in Mission, Texas, developed a TSE quite unlike BSE. 32 The findings of the initial transmission, though not of the clinical or neurohistological

examination, were communicated in October 1988 to Dr Watson, Director of the CVL, following a visit by Dr Wrathall, one of the project leaders in the Pathology Department

of the CVL, to the United States Department of Agriculture. 33 The results were not published at this point, since the attempted transmission to mice from the experimental

cow brain had been inconclusive. The results of the clinical and histological differences between scrapie-affected sheep and cattle were published in 1995. Similar studies in

which cattle were inoculated intracerebrally with scrapie inocula derived from a number of scrapie-affected sheep of different breeds and from different States, were carried

out at the US National Animal Disease Centre. 34 The results, published in 1994, showed that this source of scrapie agent, though pathogenic for cattle, did not produce the

same clinical signs of brain lesions characteristic of BSE.

http://www.bseinquiry.gov.uk/

1: J Infect Dis. 1994 Apr;169(4):814-20.

Intracerebral transmission of scrapie to cattle.

Cutlip RC, Miller JM, Race RE, Jenny AL, Katz JB, Lehmkuhl HD, DeBey BM, Robinson MM.

USDA, Agriculture Research Service, National Animal Disease Center, Ames, IA 50010.

To determine if sheep scrapie agent(s) in the United States would induce a disease in cattle resembling bovine spongiform encephalopathy, 18 newborn calves were

inoculated intracerebrally with a pooled suspension of brain from 9 sheep with scrapie. Half of the calves were euthanatized 1 year after inoculation. All calves kept longer

than 1 year became severely lethargic and demonstrated clinical signs of motor neuron dysfunction that were manifest as progressive stiffness, posterior paresis, general

weakness, and permanent recumbency. The incubation period was 14-18 months, and the clinical course was 1-5 months. The brain from each calf was examined for

lesions and for protease-resistant prion protein. Lesions were subtle, but a disease-specific isoform of the prion protein was present in the brain of all calves. Neither signs

nor lesions were characteristic of those for bovine spongiform encephalopathy.

MeSH Terms:

Animals

Brain/microbiology*

Brain/pathology

Cattle

Cattle Diseases/etiology*

Cattle Diseases/pathology

Encephalopathy, Bovine Spongiform/etiology*

Encephalopathy, Bovine Spongiform/pathology

Immunoblotting/veterinary

Immunohistochemistry

Male

Motor Neurons/physiology

Prions/analysis

Scrapie/pathology

Scrapie/transmission*

Sheep

Sleep Stages

Time Factors

Substances:

Prions

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8133096&dopt=Citation

9/13/2005

Page 16 of 17

Intracerebral transmission of scrapie to cattle FULL TEXT PDF;

SNIP...

Discussion

WE conclude that American sources of sheep scrapie are transmissible to cattle by direct intracerebral inoculation but the disease induced is NOT identical to BSE as seen

in the United Kingdom. While there were similarities in clinical signs between this experimental disease and BSE, there was no evidence of aggressiveness,

hyperexcitability, hyperesthesia (tactile or auditory), or hyperemetria of limbs as has been reported for BSE (9). Neither were there extensive neurologic lesions, which are

primary for BSE, such as severe vacuolation of neurons and neuropil or neuronal necrosis and gliosis. Although some vacuolation of neuropil, chromotolysis in neurons, and

gliosis were seen in the brains of some affected calves, these were industinguishable from those of controls. Vacuolated neurons in the red nucleus of both challenged and

normal calves were considered normal for the bovines as previously described (50).

PrP-res was found in ALL CHALLENGED CALVES REGARDLESS OF CLINCIAL SIGNS, and the amount of PrP-res positively related to the length of the incubation. ...

snip...

WE also conclude from these studies that scrapie in cattle MIGHT NOT BE RECOGNIZED BY ROUTINE HISTOPATHOLOGICAL EXAMINATION OF THE BRAIN AND

SUGGEST THAT DETECTION OF PrP-res by immunohistochemistry or immunoblotting is necessary to make a definitive diagnosis. THUS, undiagnosed scrapie infection

could contribute to the ''DOWNER-COW'' syndrome and could be responsible for some outbreaks of transmissible mink encephalopathy proposed by Burger and Hartsough

(8) and Marsh and harsough (52). ...

snip...

Multiple sources of sheep affected with scrapie and two breeds of cattle from several sources were used inthe current study in an effort to avoid a single strain of either

agent or host. Preliminary results from mouse inoculations indicate multiple strains of the agent were present in the pooled inoculum (unpublished data). ...

Transmission of the sheep scrapie to cattle was attempted in 1979 by using intracerebral, intramuscular, subcutaneous, and oral routes of inoculation of 5, 8- to 11-month

old cattlw with a homologous mixture of brain from 1 affected sheep (61, 62). ONE of the 5 cattle develped neurologic signs 48 months after inoculation. Signs were

disorientation, incoordination, a stiff-legged stilted gait, progressive difficulty in rising, and finally in terminal recumbency. The clinical course was 2.5 months. TWO of the 5

cattle similarly inoculated with brain tissue from a goat with scrapie exhibited similar signs 27 and 36 months after incoluation. Clinical courses were 43 an 44 days. Brain

lesions of mild gliosis and vacuolation and mouse inoculation data were insufficient to confirm a diagnosis of scrapie. This work remained controversial until recent

examination of the brains detected PrP-res in all 3 cattle with neurologic disease but in none of the unaffected cattle (62). Results of these studies are similar to ours and

underscore the necessity of methods other than histopathology to diagnose scrapie infection in cattle. We believe that immunologic techniques for detecting PrP-res

currently provide the most sensitive and reliable way to make a definitive diagnosis...

http://www.bseinquiry.gov.uk/files/sc/seac17/tab03.pdf

Visit to USA ... info on BSE and Scrapie

http://www.bseinquiry.gov.uk/files/yb/1988/10/00001001.pdf

http://www.ngpc.state.ne.us/cgi-bin/ultimatebb.cgi?ubb=get_topic;f=12;t=000385

12/10/76

AGRICULTURAL RESEARCH COUNCIL

REPORT OF THE ADVISORY COMMITTE ON SCRAPIE

Office Note

CHAIRMAN: PROFESSOR PETER WILDY

snip...

A The Present Position with respect to Scrapie

A] The Problem

Scrapie is a natural disease of sheep and goats. It is a slow

and inexorably progressive degenerative disorder of the nervous system

and it ia fatal. It is enzootic in the United Kingdom but not in all

countries.

The field problem has been reviewed by a MAFF working group

(ARC 35/77). It is difficult to assess the incidence in Britain for

a variety of reasons but the disease causes serious financial loss;

it is estimated that it cost Swaledale breeders alone $l.7 M during

the five years 1971-1975. A further inestimable loss arises from the

closure of certain export markets, in particular those of the United

States, to British sheep.

9/13/2005

Page 17 of 17

It is clear that scrapie in sheep is important commercially and

for that reason alone effective measures to control it should be

devised as quickly as possible.

Recently the question has again been brought up as to whether

scrapie is transmissible to man. This has followed reports that the

disease has been transmitted to primates. One particularly lurid

speculation (Gajdusek 1977) conjectures that the agents of scrapie,

kuru, Creutzfeldt-Jakob disease and transmissible encephalopathy of

mink are varieties of a single "virus". The U.S. Department of

Agriculture concluded that it could "no longer justify or permit

scrapie-blood line and scrapie-exposed sheep and goats to be processed

for human or animal food at slaughter or rendering plants" (ARC 84/77)"

The problem is emphasised by the finding that some strains of scrapie

produce lesions identical to the once which characterise the human

dementias"

Whether true or not. the hypothesis that these agents might be

transmissible to man raises two considerations. First, the safety

of laboratory personnel requires prompt attention. Second, action

such as the "scorched meat" policy of USDA makes the solution of the

acrapie problem urgent if the sheep industry is not to suffer

grievously.

snip...

76/10.12/4.6

http://www.bseinquiry.gov.uk/files/yb/1976/10/12004001.pdf

THE infamous USA SPORADIC CJDs, something to ponder;

IF the USA TSE in cattle all does not look like UK BSE, why would all USA human TSE look like UK nvCJD???

over 20 strains of scrapie documented to date with new atypical strains now being documented in sheep and goat i.e. BSE.

atypical strains of BSE/TSE showing up in cattle in different countries?

ALL animals for human/animal consumption must be tested for TSE.

ALL human TSEs must be made reportable Nationally and Internationally, OF ALL AGES...

IN a time when FSIS/APHIS/USDA/FDA et al should be strengthening the TSE regulations, it seems corporate interest has won out again over sound science and consumer

protection from an agent that is 100% fatal for the ones that go clinical. With the many different atypical TSEs showing up in different parts of the world, and with GWs BSE

MRR policy (the legal policy of trading all strains of TSEs), the battle that has waged for the last 25 years to eradicate this agent from this planet will be set back decades, if

not lost for good. ...

Terry S. Singeltary Sr.

P.O. Box 42

Bacliff, Texas USA 77518

9/13/2005

http://www.fsis.usda.gov/OPPDE/Comments/03-025IFA/03-025IFA-2.pdf


TSS

#################### https://lists.aegee.org/bse-l.html ####################
 

Kathy

Well-known member
Joined
Feb 11, 2005
Messages
837
Reaction score
0
Location
Home on the Range, Alberta
FASEB J. 2005 May;19(7):783-5. Epub 2005 Mar 9

Effect of transition metals (Mn, Cu, Fe) and deoxycholic acid (DA) on the conversion of PrPC to PrPres.
Kim NH, Choi JK, Jeong BH, Kim JI, Kwon MS, Carp RI, Kim YS.

Ilsong Institute of Life Science, Anyang, Kyounggi-do, South Korea.

The PMCA (protein misfolding cyclic amplification) technique has been shown to drive the amplification of misfolded prion protein by PrP(Sc) seeds during several cycles of incubation-sonication. Here, we report that cyclic amplification of normal hamster brain homogenates treated with a number of transition metals (manganese [Mn], copper [Cu], and iron [Fe]) leads to conversion of PrP(C) into protease-resistant PrP(res). The efficiency of PrP(res) formation and the glycoforms induced by Mn were different from those obtained by Cu and Fe. Previous results have shown higher Mn and lower Cu levels in the affinity-purified PrP(Sc) from the brain of prion diseases compared with normal hamster brain homogenates. We focused on Mn because we observed higher levels of Mn in whole brain, mitochondria, and scrapie-associated fibril-enriched fractions from the brains of animals with prion disease. In the presence of minute quantities of Mn-induced PrP(res) template with a large amount of PrP(C), PrP(res) amplification is observed. A metal chelater, EDTA reverses the effect of Mn on PrP(res) amplification, suggesting that Mn may play a role in the formation of PrP(res). It has been proposed that metal-catalyzed oxidation of PrP leads to the oxidation of amino acids and extensive aggregation of oxidized PrP. Carboxyl acids such as deoxycholic acid (DA) are oxidized molecules produced by 3' oxidation pathway. In in vitro studies, the potent effect of Mn on PrP(res) amplification is augmented by DA in a dose-dependent manner. On the basis of the evidence of the elevated Mn levels in scrapie-associated fibril (SAF)-enriched preparations from the brains of animals with prion disease, Mn-loaded PrP and oxidized molecules such as carboxyl acids may contribute to the formation of the scrapie isoform of PrP in prion diseases.

United States Patent 6,962,975
Prusiner November 8, 2005
--------------------------------------------------------------------------------
Prion protein standard and method of making the same

Abstract
The invention provides prion protein standards for use as reference materials for prion detection. The standard may be species specific, i.e. the standard is comprised of a preparation for detection of a single strain prion or it may be prepared to allow detection of multiple prion strains simultaneously. The invention also provides methods of preparing the prion protein standards using a group of non-human host mammals which have their genome manipulated with respect to genetic material related to a PrP gene such that the mammals are susceptible to infection with a prion which generally only infects an animal which is genetically diverse from the host.
--------------------------------------------------------------------------------
Inventors: Prusiner; Stanley B. (San Francisco, CA)
Assignee: The Regents of the University of California (Oakland, CA)

Patent # 6,166,187 US Patent and Trademark Office, dated December 26, 2000, filed by Dr. SB. Prusiner.

“Prions are infectious pathogens that cause central nervous system spongiform encephalopathies in humans and animals. Prions are distinct from bacteria, viruses and viroids. The predominant hypothesis at present is that no nucleic acid component is necessary for infectivity of prion protein. Further, a prion which infects one species of animal (e.g., a human) will not readily infect another (e.g., a mouse).”

In Prusiner’s most recent patent # 6,916,419, dated July 12, 2005, he clarifies: note the change.

“Prions are infectious pathogens that cause central nervous system spongiform encephalopathies in humans and animals. Prions are distinct from bacteria, viruses and viroids. The predominant hypothesis at present is that no nucleic acid component is necessary for infectivity of prion protein. Further, a prion which infects one species of animal (e.g., a human) will not infect another (e.g., a mouse).”

DR. MURALEE MURUGESU - PUBLICATION LIST

(in reverse chronological order)

2005

[25] Murugesu, M.; Wernsdorfer, W.; Hill, S.; Abboud, K. A.; Christou, G.“A large Mn25 molecular nanomagnet with S=51/2 spin ground state” J.Am. Chem. Soc. 2005, submitted.

[24] Wernsdorfer, W.; Murugesu, M.; Tasiopoulos, A. J.; Christou, G. “Field sweep rate dependence of the coercive field of single-molecule magnets:a classical approach with applications to the quantum regime” Phys.Rev. Lett. 2005, submitted.

[23]Murugesu, M.; Clérac, R.; Wernsdorfer, W.; Anson, C. E.; Powell, A. K. “Hierarchical assembly of Fe13 oxygen-bridged clusters into a close-packed superstructure” Angew. Chem. 2005, in press.

[22] Wernsdorfer, W.; Murugesu, M.; Christou, G. “Resonant Tunneling in Truly Axial Symmetry Mn12 Single-Molecule Magnets: Sharp Crossover between Thermally Assisted and Pure Quantum Tunneling” Cond-mat., 2005, 0508437.

[21] Scott, R. T. W; Parsons, S.; Murugesu, M.; Wernsdorfer, W.; Christou, G.; Brechin, E. K. “Linking manganese triangles into larger clusters: a [Mn32 ] truncated cube” Angew. Chem. 2005, in press.

[20] Milios, C. J.; Parsons, S.; Murugesu, M.; Christou, G.; Brechin, E. K. “1,1,1-tris(hydroxymethyl)propane in manganese carboxylate chemistry: synthesis, structure and magnetic properties of a mixed-valence [MnIII 4 MnII 4] cluster featuring the novel [MnIII 4 MnII 4 (3-OR)6 (2-OR)8]6+ core.” Dalton Trans. 2005, in press.

[19] Murugesu, M.; Wernsdorfer, W.; Abboud, K. A.; Christou, G. “Single-molecule magnets: synthesis, structures and magnetic properties of Mn11 and Mn25 clusters” Polyhedron, 2005, in press.

[18] Hill, S.; Anderson, N.; Wilson, A.; Takahashi, S.; Petukhov, K.; Chakov, N. E.; Murugesu, M.; North, J. M.; del Barco, E.; Kent, A. D.; Dalal, N. S.; Christou, G. “A comparison between high-symmetry Mn12 single-molecule magnets in different ligand/solvent environments” Polyhedron, 2005, in press.

[17] Hill, S.; Anderson, N.; Wilson, A.; Takahashi, S.; Chakov, N. E.; Murugesu, M.; North, J. M.; Dalal, N. S.; Christou, G. “A spectroscopic comparison between several high-symmetry S=10 Mn12 single-molecule magnets”, J. Appl. Phys. 2005, 97, 10M510.

[16] Murugesu, M.; Wernsdorfer, W.; Abboud, K. A.; Christou, G. “New structural motifs in manganese single-molecule magnetism from the use of triethanolamine ligands” Angew. Chem. 2005, 44, 792.

[15] Scott, R. T. W.; Parsons, S.; Murugesu, M.; Wernsdorfer, W.; Christou, G.; Brechin, E. K. “Synthesis, structure and magnetic properties of a trinuclear [MnIII MnII 2] single-molecule magnet” Chem. Commun. 2005, 2083.

Dr. Muregesa: Employment: August 2005 to present:
Postdoctoral Research Associate

UCB Supervisor: Professor Jeffrey R. Long

UCSF Supervisor: Professor Stanley B. Prusiner (Nobel Laureate in Medicine, 1997)

Performed intensive laboratory research in the field of transmissible spongiform encephalopathies (TSE). Engineered and subsequently tested new polyoxometallates as novel detection methods for TSEs, specifically Creutzfeldt-Jakob disease (CJD) at low concentration in mammalian samples. This research is carried out in parallel in UC Berkeley and UC San Francisco laboratories.

Study by Prusiner, et. al., entitled: “Evidence for assembly of prions with left-handed B-helices into trimers”, authors – Cedric Govaerts, Holger Wille, Stanley Prusiner, and Fred E. Cohen.

Within the context of this paper, note the following information relating to the use of “uranly acetate” :

“Although uranyl acetate is generally used as a negative stain for EM samples, it was surprising to observe that 2D crystals of prions specifically bind these ions near the center of the unit cell. This unexpected behavior provided evidence for a trimeric arrangement of PrP 27–30 monomers. We examined our model for possible uranyl-binding sites. Uranyl acetate is known to bind negatively charged side chains, but with only one Asp present in the -helical region of the PrP 27–30 model and none in the PrPSc106 model, uranyl acetate binding must occur through a different mechanism if it binds to the conformationally plastic region of PrP. Left-handed -helices expose backbone carbonyl moieties on each turn. In the center of the trimers, these moieties are often involved in the multimerization interface through H bonds with polar side chains of the neighboring monomer. Analysis of the -helical trimeric model shows that the distances between the carbonyls near the center and their interacting side chains provide suitable functionality to coordinate uranyl ions, either by replacing coordinated waters or by competing with the acetate counterion (38). In our model of PrP 27–30, Q90, H110, and D143 could be used to coordinate three to six uranyl acetate ions per trimer. This binding mode would place electron-dense uranyl ions in the center of the image, colocating with the densities observed in the EM maps.”

Uranium is a known to be slightly paramagnetic.

Dr. Murugesa is working with Long and Prusiner. Maybe you should be doing some research into single-molecule magnets (SMM).

instead of wasting our time posting inoculation studies. I admit the oral tranmission studies require a better look, but as far as injection of material (iatrogenic transmission), I have stated that there is evidence of this form of transmission, between humans. And probably, between cattle via the use of growth hormones, etc.

Thanks to modern medicine we are injecting all kinds of foreign DNA and material into our bodies. Maybe that needs a closer look as well.

Feeding trials are of value to this issue. Recombinant forms of the PrPSc have been shown to have infectivity when the natural ones did not. There is alot of conflicting information out there, and frankly, I don't trust anything coming from the French Atomic Energy Commission.

I will look at these oral transmission studies you've mentioned, but I would hope that your not blind to the conflicting presentation by Docs like Prusiner. While he is peer-reviewing studies which promote "infectivity" via consumption, he is patenting just the opposite. I think that there is more money to be made with his patent, then reviewing research papers.

We will get to the bottom on this uranyl acetate, and phosphotungsten connection with prions before to long. But considering the direction that single-molecule magnets have been taking for the last decade, I think that there should be even more concern than before, for environmental contamination by such complexes. Remember, that when you're listening to your MP3 players. Our modern technology is creating new and novel health problems along with it.
 

flounder

Well-known member
Joined
Sep 3, 2005
Messages
2,631
Reaction score
0
Location
TEXAS
EUROPEAN COMMISSION
HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL
Scientific Steering Committee
OPINION ON
ORGANOPHOSPHATE (OP) POISONING AND
HYPOTHETICAL INVOLVEMENT IN THE ORIGIN OF BSE
Background
In its opinion on possible links between BSE and Organophosphates adopted on 25-26 June
1998 and in its opinion on Hypotheses on the origin and transmission of BSE adopted on 29-
30 November 2001 the SSC concluded that there is no scientific evidence in support of the
hypothesis of an OP origin of BSE.
The issue of organophosphate poisoning has not been dealt with by the SSC so far. The
concerns expressed in the enquiries cover mainly intoxication by occupational exposure of
shepherds and farmers to OPs upon use against ecto-parasites, especially in sheep dipping and
treatment of cattle against Warble Fly infestation. Risks from residues are addressed to a
lesser extend.
In early 2003, a large number of additional enquiries on the issue have been addressed to
European Commission’s Health and Consumer Directorate General. Four of these with
substantial enclosures were by one person. Most of them are addressing both issues: chronic
organophosphate (OP) poisoning and the origin of BSE.
Information provided with the enquiries
In addition to numerous newspaper and magazine articles the enclosures to the enquiries
provide the Material Safety Data Sheet on diazinon, the OHSA Occupational Safety and
Health Guideline for Tetraethylpyrophosphate (TEPP), an US agency Hazardous Substances
Fact Sheet on crufomate, company safety information sheets, some correspondence with UK
authorities including their activities to improve safe use of these chemicals. The information
regarding claimed OP chronic poisoning of cases presented does not provide evidence, neither
for OPs being the cause for diseases nor for their exclusion (i.e., “very low” bloodcholinesterase
levels, provided without data or comparison with the normal distribution of
values; successful treatment of a patient for OP clearance without giving any OP data). It
C:\WINNT\Temporary Internet Files\SSC_Last_OP_Final.doc 2
seems however, that due to insufficient, non-prudent use of the safety requirements undue
exposures of shepherds and farmers have occurred.
There is no additional information on the claimed involvement of OPs in the origin of BSE.
This applies for both, the hypotheses on the direct effect of OPs as well as on their
hypothetical role for Cu-deficiency to be involved in the origin of BSE (Cu binding of prion
protein is known). New publications are mentioned in one enquiry but they have not yet been
provided. In an Internet search no recent scientifically valid publications were traceable. The
SSC had been informed that research would be launched on this hypothesis, but no
information has been provided so far on its status or on results.
Conclusions
a) As regards the involvement of organophosphates in the origin of BSE, no new scientific
information providing evidence or supporting the hypothesis by valid data became
available after the adoption of the last opinion of the SSC on this issue. Consequently
there is no reason for modifying the existing opinions.
b) Regarding the possibility of OP poisoning, the European legislation for registration of
plant protection products and veterinary medicines – addressed in the enquiries – provide
the basis for safe use of registered compounds and their formulations. Regarding the
alleged intoxication cases reported and OP exposure it must be concluded that safety
measures may not have been strictly followed.
References
Brown, D.R., Qin, K., Herms, J.W., Madlung, A., Manson, J., Strome, R., Fraser, P.E., Kruck, T., von
Bohlen, A., Schulz- Schaeffer, W., Giese, A., Westaway, D. and Kretzschmar, H. (1997) The Cellular
Prion Protein Binds Copper In Vivo, Nature, 390, 684-7.
Purdey, M. (2000) Ecosystems Supporting Clusters of Sporadic TSEs Demonstrate Excesses of the Radical-
Generating Divalent Cation Manganese and Deficiencies of Antioxidant Co-Factors Cu, Se, Fe, Zn Medical
Hypotheses, 54, 278-306.
Scientific Steering Committee, 1998. Opinion on possible links between BSE and Organophosphates. Adopted
on 25-26 June 1998
Scientific Steering Committee, 2001. Opinion on Hypotheses on the origin and transmission of BSE. Adopted
on 29-30 November 2001.


http://europa.eu.int/comm/food/fs/sc/ssc/out356_en.pdf


NO op's here in this study.

transmission studies do not lie, amplification and transmission!!!


1: J Infect Dis 1980 Aug;142(2):205-8


Oral transmission of kuru, Creutzfeldt-Jakob disease, and scrapie to
nonhuman primates.

Gibbs CJ Jr, Amyx HL, Bacote A, Masters CL, Gajdusek DC.

Kuru and Creutzfeldt-Jakob disease of humans and scrapie disease of
sheep and goats were transmitted to squirrel monkeys (Saimiri
sciureus) that were exposed to the infectious agents only by their
nonforced consumption of known infectious tissues. The asymptomatic
incubation period in the one monkey exposed to the virus of kuru was
36 months; that in the two monkeys exposed to the virus of
Creutzfeldt-Jakob disease was 23 and 27 months, respectively; and
that in the two monkeys exposed to the virus of scrapie was 25 and
32 months, respectively. Careful physical examination of the buccal
cavities of all of the monkeys failed to reveal signs or oral
lesions. One additional monkey similarly exposed to kuru has
remained asymptomatic during the 39 months that it has been under
observation.

PMID: 6997404

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6997404&dopt=Abstract

TSS
 

Kathy

Well-known member
Joined
Feb 11, 2005
Messages
837
Reaction score
0
Location
Home on the Range, Alberta
Terry is concerned only with transmission of the disease, and refuses to look at the causes of cases which did not occur through an artificial (induction, transmission, inoculation) manner - which remains very debatable - as to what is being transmitted and causing the disease.

His insistance upon bring up organophosphates when I was not speaking of them, is baffling. Why do you ignore my comments about the single-molecule magnets, Terry? This is a direction of science which is melding organic biology with chemistry.

Once it is finally unravelled, I believe, we will see that all mammals which produce PrPC are all capable of producing, spontaneously, complexes which act as single-molecule magnets (SMMs) within their bodies. Since the science, so far, has shown that most SMMs are composed of manganese complexes, it is not unreasonable to think that it is possible that the manganese based scrapie fibrils are behaving like single-molecule magnets (which bind head to head, tail to tail - forming prion rods). Aging of amyloids can cause further tertiary changes, which depending upon what other contaminants they have bound with, leads to differing diseases.
 

flounder

Well-known member
Joined
Sep 3, 2005
Messages
2,631
Reaction score
0
Location
TEXAS
kathy,

thought i might bring this to your attention, just to show you i am not biased;-) indeed yes, transmission and amplification is what i have been interested in since the beginning. we know how to stop that. it will be interesting what they study finds though. i applaud your efforts. ...


SPONGIFORM ENCEPHALOPATHY ADVISORY COMMITTEE

Draft minutes of the open session of the 90th meeting held on 24th

November 2005





snip...



65. A member who was involved in the EU FatePride study explained

that biochemists and geochemists were trying to determine the role

of environmental factors (e.g. distribution of metals in the soil,

presence of organophosphate pesticides) in the development of

prion diseases such as BSE, scrapie and CJD. The study was

likely to be extended until mid 2006 and when it was finished, he

would report the findings to SEAC.





snip...



http://www.seac.gov.uk/minutes/final90.pdf




kind regards,
terry
 

Kathy

Well-known member
Joined
Feb 11, 2005
Messages
837
Reaction score
0
Location
Home on the Range, Alberta
Thanks for the link Terry. Here are a couple articles of interest, which I had posted on a different link. Dr. Ragnarsdottir is also working with FATEPRIDE.

Environmental fate and toxicology of organophosphate pesticides
Author: RAGNARSDOTTIR K.V.1
Source: Journal of the Geological Society, Volume 157, Number 4, July 2000, pp. 859-876(18)

Abstract:
Organophosphate pesticides (OPs) are generally regarded as safe for use on crops and animals due to their relatively fast degradation rates. Their degradation varies as a function of microbial composition, pH, temperature, and availability of sunlight. Under laboratory conditions (25°C and pH 7) biodegradation is about one order of magnitude faster than chemical hydrolysis, which in turn is roughly ten times faster than photolysis. Microbial biomass often needs a lengthy adaptation period in which soil bacteria mutate to be able to metabolize OPs. Biodegradation is thus in general an order of magnitude faster in soils that have had repeated applications of OPs compared to control soils which have never had OP applications. Because OPs are relatively soluble, they often enter surface and groundwaters. In the latter OPs are primarily broken down through chemical hydrolysis, which is pH dependent. Hydrolysis half-life of an OP pesticide of 10 days in the laboratory increases to one year if the pH of the water is 6 and the temperature 5°C, suggesting that OPs can persist in the environment for long periods of time. Indeed, OPs are detected in soils years after application. Why this environmental persistence occurs is not clear, but it may be due to sorption of the OPs to soil particles, making them unavailable for microbial metabolism. Example calculations and literature data show that conditions can occur in soil where OPs are preserved and transferred to humans through food. A review of the literature shows that OPs are highly toxic and that human exposure is undesirable. Evidence suggests that OPs are mutagenic and teratogenic and that a large number of modern-day diseases of the nervous and immune system of mammals can be linked to these pesticides. These include BSE (mad cows disease), CJD, Gulf War syndrome, Parkinson's disease and multiple sclerosis, arguing for a thorough examination of the environmental fate and toxicology of OPs as well as their use.

Affiliations: 1: Department of Earth Sciences, University of Bristol, Bristol BS8 1RJ, UK (e-mail: [email protected])



There is also a Dr. John Giesy coming to the University of Saskatchewan in 2006 to study these environmental problems.


World-leading Environmental Toxicologist to Join U of S

Released June 27, 2005

John Giesy, a world-renowned expert in industrial pollutants and their effect on people and the environment, has been appointed Canada Research Chair in Environmental Toxicology at the University of Saskatchewan, the federal government announced today.

The U of S was awarded $1.4 million over the next seven years for the Chair, as well as $906,000 from the Canada Foundation for Innovation (CFI), the University, and other partners to buy related laboratory equipment.

“Environmental sustainability is becoming ever more critical as populations grow and industrial society puts pressure on the natural systems that sustain us,” said U of S Vice-President Research Steven Franklin. “Professor Giesy’s appointment is part of the University of Saskatchewan’s vigorous response to these urgent issues, both in discovery research and in training the next generation of environmental scientists.”

Giesy, currently Distinguished Professor of Zoology at Michigan State University, will assume his position with the U of S department of veterinary and biomedical sciences in May, 2006. His work will be based at lab facilities in the U of S Toxicology Centre, newly rebuilt and refurbished to accommodate a robust research program to study industry-produced persistent organic pollutants (POPs).

“It is the opportunity of a lifetime to be able work in a program the calibre of that at the U of S,” Giesy said. “It is a great university in a great country and I cannot wait to get started. All of the people I have met and all of the interactions at U of S have been first class all the way.”

Giesy will work to develop rapid, sensitive, and cost-effective tools to test for POPs in the environment, particularly in regions such as Canada’s Arctic where fragile ecosystems and a heavy reliance on native foods make populations especially vulnerable. Ultimately, these tools and the knowledge generated will guide policy makers and regulators in prescribing more environmentally sustainable practices.

Giesy was the first to identify the presence in the environment of perfluorinated compounds, a class of POPs used in common products such as paints, cosmetics, and electronics. Though it had been thought that these chemicals didn’t migrate through the environment, Giesy and his colleagues detected the compounds in animal tissues from all over the world -- from Ganges River dolphins to North American bald eagles. It is still unclear what effect these chemicals may have on wildlife and people.

Another of his “firsts” is the discovery that some POPs become more toxic when exposed to light. He has also worked on the long-term effects of Agent Orange on Vietnam War veterans, as well as the hormone-disrupting effects of other POPs on reproductive systems in wildlife.

Giesy is also adept at “green chemistry” – the design of more environmentally friendly alternatives.

Giesy will lead a world-class training program in eco-toxicology. His group is expected to include 16 graduate students and five post doctoral fellows, as well as employ five research technicians and attract three to five visiting scientists at any given time.

Over the last three decades, his research programs have garnered more than $57 million in funding and resulted in more than 550 publications, making him the fourth most-cited author in ecology and environmental science. He is past president of the Society of Environmental Toxicology and Chemistry, the world-wide leading academic organization in his field. He has also received many of the world’s top awards in environmental science, including the prestigious Vollenweider Lectureship from Environment Canada.

With the addition of Giesy’s Chair, the U of S has now been awarded nearly $28 million to support 29 Chairs, as well as nearly $10.4 million in related CFI and partner infrastructure funding.

A team of academic peers chooses the most outstanding candidates from nominations submitted to the Canada Research Chairs program by universities. Giesy’s chair is one of 79, together worth $62.9 million, announced today in Charlottetown.

“Our universities are vital centres of cutting-edge research and innovation,” said Industry Minister David Emerson. “The ideas generated at these institutions extend the frontiers of knowledge and create a deeper understanding of the complex world in which we live.”

The $900-million Canada Research Chairs Program was created to enhance universities as centers of world-class research excellence by attracting and retaining excellent researchers in Canadian universities. When fully implemented, Canadian universities will have 2,000 new Canada Research Chairs. For profiles of U of S Canada Research Chair holders, visit http://www.usask.ca/crc or the national website at http://www.chairs.gc.ca.

For more information, contact:

John Geisy
Professor
Zoology Department, Michigan State University
(517) 353-2000
 

Latest posts

Top